<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Transl Int Med</journal-id><journal-id journal-id-type="iso-abbrev">J Transl Int Med</journal-id><journal-id journal-id-type="publisher-id">jtim</journal-id><journal-id journal-id-type="doi">jtim</journal-id><journal-title-group><journal-title>Journal of Translational Internal Medicine</journal-title></journal-title-group><issn pub-type="ppub">2450-131X</issn><issn pub-type="epub">2224-4018</issn><publisher><publisher-name>De Gruyter</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC10732498</article-id><article-id pub-id-type="publisher-id">jtim-2023-0122</article-id><article-id pub-id-type="doi">10.2478/jtim-2023-0122</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Circular RNA: A promising new star of vaccine</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Xie</surname><given-names>Jindong</given-names></name><xref rid="j_jtim-2023-0122_aff_001" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Ye</surname><given-names>Fengxi</given-names></name><xref rid="j_jtim-2023-0122_aff_002" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Deng</surname><given-names>Xinpei</given-names></name><xref rid="j_jtim-2023-0122_aff_001" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Tang</surname><given-names>Yuhui</given-names></name><xref rid="j_jtim-2023-0122_aff_001" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Liang</surname><given-names>Jie-Ying</given-names></name><xref rid="j_jtim-2023-0122_aff_003" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Xufeng</given-names></name><xref rid="j_jtim-2023-0122_aff_004" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Sun</surname><given-names>Yuying</given-names></name><xref rid="j_jtim-2023-0122_aff_001" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Tang</surname><given-names>Hailin</given-names></name><xref rid="j_jtim-2023-0122_aff_001" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Lei</surname><given-names>Jinsong</given-names></name><xref rid="j_jtim-2023-0122_aff_001" ref-type="aff"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1912-0216</contrib-id><name><surname>Zheng</surname><given-names>Shaoquan</given-names></name><email xlink:href="mailto:zhengshq3@mail2.sysu.edu.cn">zhengshq3@mail2.sysu.edu.cn</email><xref rid="j_jtim-2023-0122_aff_001" ref-type="aff"/><xref rid="j_jtim-2023-0122_aff_005" ref-type="aff"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5205-9923</contrib-id><name><surname>Zou</surname><given-names>Yutian</given-names></name><email xlink:href="mailto:zouyt@sysucc.org.cn">zouyt@sysucc.org.cn</email><xref rid="j_jtim-2023-0122_aff_001" ref-type="aff"/></contrib><aff id="j_jtim-2023-0122_aff_001"><institution>State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center</institution>, <city>Guangzhou</city>
<postal-code>510060</postal-code>, <addr-line>Guangdong Province</addr-line>, <country country="CN">China</country></aff><aff id="j_jtim-2023-0122_aff_002"><institution>Zhongshan School of Medicine, Sun Yat-sen University</institution>, <city>Guangzhou</city>
<postal-code>510060</postal-code>, <addr-line>Guangdong Province</addr-line>, <country country="CN">China</country></aff><aff id="j_jtim-2023-0122_aff_003"><institution>Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Department of Medical Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University</institution>, <city>Guangzhou</city>
<postal-code>510000</postal-code>, <addr-line>Guangdong Province</addr-line>, <country country="CN">China</country></aff><aff id="j_jtim-2023-0122_aff_004"><institution>Department of Data Science and Visualization, Faculty of Informatics, University of Debrecen</institution>, <city>Debrecen</city>, <country country="HU">Hungary</country></aff><aff id="j_jtim-2023-0122_aff_005"><institution>Breast Disease Center, The First Affiliated Hospital of Sun Yat-sen University</institution>, <city>Guangzhou</city>
<postal-code>510000</postal-code>, <addr-line>Guangdong Province</addr-line>, <country country="CN">China</country></aff></contrib-group><author-notes><p># These authors contributed equally to this work.</p></author-notes><pub-date date-type="pub" publication-format="electronic"><day>20</day><month>12</month><year>2023</year></pub-date><pub-date date-type="collection" publication-format="electronic"><month>12</month><year>2023</year></pub-date><volume>11</volume><issue>4</issue><fpage>372</fpage><lpage>381</lpage><permissions><copyright-statement>&#x000a9; 2023 Jindong Xie, Fengxi Ye, Xinpei Deng, Yuhui Tang, Jie-Ying Liang, Xufeng
Huang, Yuying Sun, Hailin Tang, Jinsong Lei, Shaoquan Zheng, Yutian Zou, published by De Gruyter on behalf of Scholar Media Publishing</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Jindong Xie, Fengxi Ye, Xinpei Deng, Yuhui Tang, Jie-Ying Liang, Xufeng
Huang, Yuying Sun, Hailin Tang, Jinsong Lei, Shaoquan Zheng, Yutian Zou, published by De Gruyter on behalf of Scholar Media Publishing</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This work is licensed under the Creative Commons Attribution 4.0 International License.</license-p></license></permissions><abstract><title>Abstract</title><p>Circular RNAs (circRNAs) are a class of single-stranded RNAs with covalently closed structures. Owing to their not having 3' or 5' ends, circRNAs are highly durable and insusceptible to exonuclease-mediated degradation. Moreover, some circRNAs with certain structures are translatable, making them novel vaccines. Vaccines are efficient tools for immunotherapy, such as for the prevention of infectious diseases and cancer treatment. The immune system is activated during immunotherapy to fight against abnormal allies or invaders. CircRNA vaccines represent a potential new avenue in the vaccine era. Recently, several circRNA vaccines have been synthesized and tested <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic>. Our review briefly introduces the current understanding of the biology and function of translatable circRNAs, molecular biology, synthetic methods, delivery of circRNA, and current circRNA vaccines. We also discussed the challenges and future directions in the field by summarizing the developments in circRNA vaccines in the past few years.</p></abstract><kwd-group><title>Key words</title><kwd>circular RNA</kwd><kwd>vaccine</kwd><kwd>drug delivery</kwd><kwd>immunotherapy</kwd></kwd-group><funding-group><funding-statement>This research was supported by the China Postdoctoral Science Foundation (2022M720178, Shaoquan Zheng).
</funding-statement></funding-group><counts><page-count count="10"/></counts></article-meta></front><body><sec id="j_jtim-2023-0122_s_001"><title>Introduction</title><p>Vaccines are essential for the maintenance of human health. They are the most efficient tools for infectious disease prevention and among the most promising methods for fighting cancer. The vaccination era began in the late 18th century when Edward Jenner invented the first vaccine to induce preventive immunity in the human body to protect against deadly smallpox.<sup>[<xref rid="j_jtim-2023-0122_ref_001" ref-type="bibr">1</xref>]</sup> Since then, vaccine strategies have evolved from live pathogen inactivation or attenuation techniques to the construction of biologically modified proteins or peptide antigens and eventually to the use of nucleic acids to induce <italic toggle="yes">in vivo</italic> antigen-encoding.<sup>[<xref rid="j_jtim-2023-0122_ref_002" ref-type="bibr">2</xref>,<xref rid="j_jtim-2023-0122_ref_003" ref-type="bibr">3</xref>]</sup> Although advancements in conventional vaccine approaches have had success in controlling infectious diseases and cancer therapy, challenges remain, and breakthroughs in vaccine technologies are necessary.<sup>[<xref rid="j_jtim-2023-0122_ref_004" ref-type="bibr">4</xref>]</sup> For example, mRNA vaccines, such as BNT162B2<sup>[<xref rid="j_jtim-2023-0122_ref_005" ref-type="bibr">5</xref>,<xref rid="j_jtim-2023-0122_ref_006" ref-type="bibr">6</xref>]</sup> and Chadox1<sup>[<xref rid="j_jtim-2023-0122_ref_007" ref-type="bibr">7</xref>]</sup> have reduced the hospitalization rates of patients infected with the SARS-Cov-2 alpha-variant, but their effectiveness in delta-variant patients is considerably lower than that.<sup>[<xref rid="j_jtim-2023-0122_ref_008" ref-type="bibr">8</xref>, <xref rid="j_jtim-2023-0122_ref_009" ref-type="bibr">9</xref>, <xref rid="j_jtim-2023-0122_ref_010" ref-type="bibr">10</xref>]</sup> Moreover, the protein-encoding functions of circRNAs were demonstrated, and a new type of vaccine using circRNAs as a platform was developed and proved efficient <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic>. These single-stranded RNAs are perfect vaccine carriers because they are highly durable and invulnerable to exonuclease owing to the inaccessibility of free 5&#x02019; or 3&#x02019; ends.<sup>[<xref rid="j_jtim-2023-0122_ref_011" ref-type="bibr">11</xref>]</sup> Moreover, they have several advantages that facilitate their use as cost-effective vaccines.</p></sec><sec id="j_jtim-2023-0122_s_002"><title>Overview of circular RNA</title><sec id="j_jtim-2023-0122_s_002_s_001"><title>Structure and biogenesis</title><p>Circular RNA is a prominent feature of the transcriptomes of many metazoans, including those in humans.<sup>[<xref rid="j_jtim-2023-0122_ref_012" ref-type="bibr">12</xref>, <xref rid="j_jtim-2023-0122_ref_013" ref-type="bibr">13</xref>, <xref rid="j_jtim-2023-0122_ref_014" ref-type="bibr">14</xref>, <xref rid="j_jtim-2023-0122_ref_015" ref-type="bibr">15</xref>]</sup> Once thought to be meaningless by-products of splicing errors,<sup>[<xref rid="j_jtim-2023-0122_ref_016" ref-type="bibr">16</xref>]</sup> circRNAs are expressed in cell-specific, tissue-specific, and developmental stage-specific patterns.<sup>[<xref rid="j_jtim-2023-0122_ref_017" ref-type="bibr">17</xref>, <xref rid="j_jtim-2023-0122_ref_018" ref-type="bibr">18</xref>, <xref rid="j_jtim-2023-0122_ref_019" ref-type="bibr">19</xref>]</sup> Known as a type of covalently closed single-stranded RNA without accessible 5&#x02019; or 3&#x02019;ends, circRNAs are usually produced by classical linear splicing and RNA back-splicing.<sup>[<xref rid="j_jtim-2023-0122_ref_020" ref-type="bibr">20</xref>, <xref rid="j_jtim-2023-0122_ref_021" ref-type="bibr">21</xref>, <xref rid="j_jtim-2023-0122_ref_022" ref-type="bibr">22</xref>]</sup> Some circRNAs originate from tRNA splicing reactions.<sup>[<xref rid="j_jtim-2023-0122_ref_023" ref-type="bibr">23</xref>]</sup> For example, tric31905 is a circular RNA transcript derived from the fruit fly tRNA gene CR31905<sup>[<xref rid="j_jtim-2023-0122_ref_023" ref-type="bibr">23</xref>]</sup> and the circular tRNA<sup>Trp</sup> intron is a highly stable circRNA in <italic toggle="yes">Haloferax volcanii</italic>.<sup>[<xref rid="j_jtim-2023-0122_ref_024" ref-type="bibr">24</xref>]</sup> Linear splicing generally forms intronic circRNAs, upon which an intron lariat that can avoid debranching is created when an upstream donor splice site is ligated to a downstream acceptor splice site.<sup>[<xref rid="j_jtim-2023-0122_ref_020" ref-type="bibr">20</xref>]</sup> Back-splicing is a process through which a 3&#x02032;, 5&#x02032;-phosphodiester bond is formed between the 3&#x02032;-end of an exon and the 5&#x02032;-end of either its or an upstream exon, creating a closed structure with a back-splicing junction site.<sup>[<xref rid="j_jtim-2023-0122_ref_012" ref-type="bibr">12</xref>,<xref rid="j_jtim-2023-0122_ref_025" ref-type="bibr">25</xref>]</sup> Most circRNAs are exon-containing and are derived from the back-splicing of precursor messenger RNA exons in a spliceosome-dependent manner. However, a small portion of intronic circRNAs originates from the processing of cellular non-coding sequences.<sup>[<xref rid="j_jtim-2023-0122_ref_026" ref-type="bibr">26</xref>]</sup> For example, circRNAs can be detected as processing intermediates during rRNA maturation in archaea.<sup>[<xref rid="j_jtim-2023-0122_ref_024" ref-type="bibr">24</xref>]</sup> circRNA biogenesis is modulated by various distinct factors.<sup>[<xref rid="j_jtim-2023-0122_ref_017" ref-type="bibr">17</xref>]</sup> Studies have revealed that back-splicing requires spliceosomal machinery as a catalyst and is regulated by both RNA-binding proteins and intronic complementary sequences.<sup>[<xref rid="j_jtim-2023-0122_ref_027" ref-type="bibr">27</xref>, <xref rid="j_jtim-2023-0122_ref_028" ref-type="bibr">28</xref>, <xref rid="j_jtim-2023-0122_ref_029" ref-type="bibr">29</xref>]</sup> However, additional regulatory factors that influence circRNA biogenesis require further research.</p></sec><sec id="j_jtim-2023-0122_s_002_s_002"><title>Function</title><p>circRNAs participate in various biological processes, such as cellular activity modulation, gene and protein sponging, cell proliferation, tumor progression, and immune regulation.<sup>[<xref rid="j_jtim-2023-0122_ref_030" ref-type="bibr">30</xref>, <xref rid="j_jtim-2023-0122_ref_031" ref-type="bibr">31</xref>, <xref rid="j_jtim-2023-0122_ref_032" ref-type="bibr">32</xref>, <xref rid="j_jtim-2023-0122_ref_033" ref-type="bibr">33</xref>, <xref rid="j_jtim-2023-0122_ref_034" ref-type="bibr">34</xref>, <xref rid="j_jtim-2023-0122_ref_035" ref-type="bibr">35</xref>, <xref rid="j_jtim-2023-0122_ref_036" ref-type="bibr">36</xref>, <xref rid="j_jtim-2023-0122_ref_037" ref-type="bibr">37</xref>]</sup> For decades, circRNAs have been considered untranslatable because they do not have 5&#x02019;caps,<sup>[<xref rid="j_jtim-2023-0122_ref_038" ref-type="bibr">38</xref>,<xref rid="j_jtim-2023-0122_ref_039" ref-type="bibr">39</xref>]</sup> and cap-independent translation was discovered to allow circRNA translation;<sup>[<xref rid="j_jtim-2023-0122_ref_040" ref-type="bibr">40</xref>]</sup> further investigations have provided evidence for their ubiquity.<sup>[<xref rid="j_jtim-2023-0122_ref_041" ref-type="bibr">41</xref>]</sup> Based on the previous study, Kozak consensus sequences, m6A-modification, and internal ribosome entry sites (IRES) can initiate protein translation from circRNA without 5&#x02032; caps.<sup>[<xref rid="j_jtim-2023-0122_ref_020" ref-type="bibr">20</xref>]</sup> The traits of circRNAs associated with their coding capability are as follows: (1) the presence of IRES in open reading frames (ORFs), N6-methyladenosine (m6A) RNA modification, or Kozak consensus sequences <sup>[<xref rid="j_jtim-2023-0122_ref_042" ref-type="bibr">42</xref>]</sup>; (2) ribosome association by ribosome profiling; and (3) translated peptides from back-splicing junction sites.<sup>[<xref rid="j_jtim-2023-0122_ref_043" ref-type="bibr">43</xref>]</sup> According to the literature, circRNAs with nuclear localization are virtually untranslated, and hundreds of circRNAs localized in the cytoplasm are translatable.<sup>[<xref rid="j_jtim-2023-0122_ref_043" ref-type="bibr">43</xref>,<xref rid="j_jtim-2023-0122_ref_044" ref-type="bibr">44</xref>]</sup> CircRNAs could be incorporated into the 40S subunit of eukaryotic ribosomes <italic toggle="yes">via</italic> IRES, which are upstream of the circRNA start codon (first identified in picornavirus mRNAs), and are thereby translated by ribosomes.<sup>[<xref rid="j_jtim-2023-0122_ref_045" ref-type="bibr">45</xref>]</sup> Evidence has shown that either the complementary regions of 18S rRNA or a structured RNA element in circRNAs can facilitate circRNA translation in an IRES-dependent manner.<sup>[<xref rid="j_jtim-2023-0122_ref_046" ref-type="bibr">46</xref>]</sup> Moreover, by recruiting the m6A reader YTHDF3 and translation initiation factor eIF4G2, m6A modifications can initiate circRNA translation.<sup>[<xref rid="j_jtim-2023-0122_ref_047" ref-type="bibr">47</xref>,<xref rid="j_jtim-2023-0122_ref_048" ref-type="bibr">48</xref>]</sup> Proteins translated from circRNAs are involved in various physiological functions, including the regulation of cell proliferation, differentiation, migration, and myogenesis.<sup>[<xref rid="j_jtim-2023-0122_ref_049" ref-type="bibr">49</xref>, <xref rid="j_jtim-2023-0122_ref_050" ref-type="bibr">50</xref>, <xref rid="j_jtim-2023-0122_ref_051" ref-type="bibr">51</xref>, <xref rid="j_jtim-2023-0122_ref_052" ref-type="bibr">52</xref>, <xref rid="j_jtim-2023-0122_ref_053" ref-type="bibr">53</xref>]</sup> The protein-coding ability of circRNAs enables their potential use as cancer vaccines.</p></sec><sec id="j_jtim-2023-0122_s_002_s_003"><title>Characteristics that enable circRNA&#x02019;s use as vaccines</title><p>circRNAs have unique characteristics that enable their use as vaccines. Because circRNAs have a covalently closed structure and no termini, circRNAs are immune to degradation mediated by exonucleases, conserving a higher stability than their linear mRNA isoforms. <sup>[<xref rid="j_jtim-2023-0122_ref_011" ref-type="bibr">11</xref>,<xref rid="j_jtim-2023-0122_ref_025" ref-type="bibr">25</xref>,<xref rid="j_jtim-2023-0122_ref_054" ref-type="bibr">54</xref>,<xref rid="j_jtim-2023-0122_ref_055" ref-type="bibr">55</xref>]</sup> In mammalian cells, the intermediate half-life of circRNAs is at least 2.5 times more than that of their linear counterparts.<sup>[<xref rid="j_jtim-2023-0122_ref_056" ref-type="bibr">56</xref>]</sup> The safe antigen production of circRNA-based vaccines can be ensured by circRNAs&#x02019; ability to be expressed endogenously.<sup>[<xref rid="j_jtim-2023-0122_ref_041" ref-type="bibr">41</xref>,57&#x02013;59]</sup> circRNAs such as circZNF609,<sup>[<xref rid="j_jtim-2023-0122_ref_053" ref-type="bibr">53</xref>]</sup> circMbl,<sup>[<xref rid="j_jtim-2023-0122_ref_060" ref-type="bibr">60</xref>]</sup> and circSfl <sup>[<xref rid="j_jtim-2023-0122_ref_061" ref-type="bibr">61</xref>]</sup> are associated with polyribosomes and can generate functional proteins that play a role in cell biology.<sup>[<xref rid="j_jtim-2023-0122_ref_049" ref-type="bibr">49</xref>,<xref rid="j_jtim-2023-0122_ref_051" ref-type="bibr">51</xref>,<xref rid="j_jtim-2023-0122_ref_062" ref-type="bibr">62</xref>]</sup> Without integrating into the genome, circRNA-based vaccines can be translated into antigens in the cytoplasm. In addition, another study demonstrated that synthetic circRNAs derived from foreign introns triggered effective immune responses and inhibited infection <italic toggle="yes">via</italic> the RNA pattern recognition receptor retinoic-acid-inducible gene-I-dependent pathway.<sup>[<xref rid="j_jtim-2023-0122_ref_063" ref-type="bibr">63</xref>]</sup> These findings indicate that circRNAs can induce innate immune responses and implies that their immunogenicity could be used in creating circRNA self-adjuvant vaccines.<sup>[<xref rid="j_jtim-2023-0122_ref_063" ref-type="bibr">63</xref>]</sup> Although literature has widely accepted that the translation efficiency of circRNAs in a CAP-independent manner is relatively lower than that of linear RNAs in a CAP-dependent manner, a recent study proposed a different view: circRNAs have high translation efficiency owing to their covalently closed topology. This unique structure allows ribosomes to pass over the length of circRNAs even after reaching a stop codon, which makes it easier to re-initiate translation.<sup>[<xref rid="j_jtim-2023-0122_ref_064" ref-type="bibr">64</xref>]</sup> In addition, studies have shown that the rolling circle translation of circRNAs is enabled by their covalently closed topology.<sup>[<xref rid="j_jtim-2023-0122_ref_040" ref-type="bibr">40</xref>,<xref rid="j_jtim-2023-0122_ref_042" ref-type="bibr">42</xref>,<xref rid="j_jtim-2023-0122_ref_065" ref-type="bibr">65</xref>]</sup> Moreover, as recent studies have demonstrated,<sup>[<xref rid="j_jtim-2023-0122_ref_066" ref-type="bibr">66</xref>,<xref rid="j_jtim-2023-0122_ref_067" ref-type="bibr">67</xref>]</sup> engineering circRNAs can enhance their translation efficiency and lead to more stable protein production than that of their linear counterparts.</p><p>Because of inherent stability, immunogenicity, achievable high translation efficiency through engineering, and an inevitable need for nucleotide modifications (which are required for mRNA production <italic toggle="yes">via</italic> the <italic toggle="yes">in vitro</italic> transcription [IVT] pathway for the improvement of mRNA stability without increasing the likelihood of unwanted immunogenicity<sup>[<xref rid="j_jtim-2023-0122_ref_068" ref-type="bibr">68</xref>]</sup>), we posit that circRNAs have the better potency to be developed into vaccines than mRNA.</p></sec></sec><sec id="j_jtim-2023-0122_s_003"><title>Molecular biology of circRNA vaccine</title><sec id="j_jtim-2023-0122_s_003_s_001"><title>Structure of vaccine</title><p>The circRNA vaccine is a subtype of the nucleic acid vaccine that can be delivered with or without a carrier; thus, the circRNA can be administered directly in a naked form or encapsulated in delivery carriers, such as lipid nanoparticles (LNPs). Modified circRNAs generally comprise coding regions for vaccine antigens, untranslated regions, promoters, IRES, permuted intron-exon (PIE) systems, RNA spacers, and homology arms. IRES are internal ribosome entry sites placed before the coding sequences to initiate translation. Homology arms and rationally designed spacers are constructed to increase circularization efficiency.<sup>[<xref rid="j_jtim-2023-0122_ref_069" ref-type="bibr">69</xref>]</sup></p></sec><sec id="j_jtim-2023-0122_s_003_s_002"><title>Mechanisms of circRNA vaccine-mediated immunotherapy</title><p>CircRNA vaccines are promising candidates for disease-related immunotherapies, such as the prevention of infectious diseases and cancer treatment. CircRNA vaccines can generate corresponding proteins <italic toggle="yes">via</italic> translation after injection. These heterologous gene expression products can directly affect immune cells. They induce and reinforce innate and adaptive immunity by stimulating the activation and proliferation of immune cells, reinforcing the host&#x02019;s ability to fight viruses and tumors. For example, Yang <italic toggle="yes">et al</italic>. reported that direct administration of a circular mRNA (cmRNA) mixture that encodes four cytokines into tumors can lead to T cell activation (both CD4<sup>+</sup> and CD 8<sup>+</sup> T cells) and promote immune cell penetration into the tumor, exerting a strong antitumor effect.<sup>[<xref rid="j_jtim-2023-0122_ref_070" ref-type="bibr">70</xref>]</sup></p><p>There is evidence that the activation of immunostimulatory RNA receptors in cells can intrinsically induce immunogenic circRNAs.<sup>[<xref rid="j_jtim-2023-0122_ref_063" ref-type="bibr">63</xref>]</sup> Owing to their immunogenicity, circRNAs can serve as self-adjuvanted vaccinations. For example, in studies led by Qu L and colleagues, the CircRNA<sup>RBD</sup> vaccine triggered distinct Th1-skewed immune responses and brought about neutralizing antibody elicitation in a large proportion of patients,<sup>[<xref rid="j_jtim-2023-0122_ref_071" ref-type="bibr">71</xref>]</sup> suggesting activated innate immune responses.</p></sec><sec id="j_jtim-2023-0122_s_003_s_003"><title>Advantages of circRNA vaccine</title><p>The most commonly used vaccines are based on pathogens, DNA, and proteins/peptides, each of which has distinct features and limitations. For example, mRNA-based vaccines have short half-lives and are susceptible to exonuclease digestion. Therefore, they require a strictly controlled sterile environment free of ribonucleases during the entire production procedure and a low-temperature cold chain for storage and distribution.<sup>[<xref rid="j_jtim-2023-0122_ref_072" ref-type="bibr">72</xref>]</sup> DNA-based vaccines have the potential for genome integration.<sup>[<xref rid="j_jtim-2023-0122_ref_073" ref-type="bibr">73</xref>]</sup></p><p>Owing to their unique properties, circRNA vaccines are better than conventional vaccines. First, because circRNAs can produce more significant amounts of proteins for a longer duration than linear RNAs,<sup>[<xref rid="j_jtim-2023-0122_ref_069" ref-type="bibr">69</xref>]</sup> circRNA vaccines probably have high translation efficiency. The translated products would have prolonged expression. Second, the literature synthesized circRNAs that, even in modest quantities, expressed particular antigens highly immunogenic for DC presentation.<sup>[<xref rid="j_jtim-2023-0122_ref_074" ref-type="bibr">74</xref>]</sup> This feature results in circRNAs having potential for use in highly efficient vaccines. Third, circRNA-LNPs exhibited greater thermostability than linear mRNA-LNP vaccines. The literature reported that circular RNA vaccines encapsulated in LNPs were conserved well for no less than 4 weeks at 4&#x000b0;C and approximately 30 d at room temperature.<sup>[<xref rid="j_jtim-2023-0122_ref_020" ref-type="bibr">20</xref>]</sup></p><p>However, the limitations and disadvantages of the circRNA vaccines remain unclear. For example, circRNA immunogenicity can be a double-edged sword. Although the immunogenicity of circRNAs enables highly efficient circRNA vaccines, whether this characteristic would inhibit vaccine development remains unclear.<sup>[<xref rid="j_jtim-2023-0122_ref_075" ref-type="bibr">75</xref>]</sup> Moreover, the safety concerns of circRNA vaccines require further research. In addition, the techniques for generating circRNA vaccines are immature for large-scale vaccine production. Thus, further investigations are necessary before circRNA vaccines can be used in clinical trials.</p></sec></sec><sec id="j_jtim-2023-0122_s_004"><title>Approaches to synthesize circRNA vaccine</title><p>Generally, circRNAs are produced by the synthesis of one or more precursor linear RNAs, followed by RNA circularization to generate a covalently closed loop, which is often mediated by chemical or enzymatic ligation methods.<sup>[<xref rid="j_jtim-2023-0122_ref_076" ref-type="bibr">76</xref>]</sup></p><sec id="j_jtim-2023-0122_s_004_s_001"><title>Designing the constructs/backbone of circRNA and linear RNA</title><p>A significant challenge in the synthesis of circRNAs is their inability to progress through the standard cap-dependent procedure used to initiate translation. Several strategies have been developed to overcome this limitation. Two main mechanisms allow for endogenous circRNA translation in a cap-independent manner: m6A alteration of the region located close upstream of the start codon and a virally originated IRES upstream of the circular sequence containing the ORF. m6A modification refers to the methylation of N6 in the nitrogenous base adenine,<sup>[<xref rid="j_jtim-2023-0122_ref_077" ref-type="bibr">77</xref>]</sup> which is the most pervasive modification in eukaryotes.<sup>[<xref rid="j_jtim-2023-0122_ref_078" ref-type="bibr">78</xref>]</sup> IRES, a structured RNA element located upstream of the start codon, can initiate translation without the presence of a 5&#x02032; cap by recruiting eukaryotic ribosomes.<sup>[<xref rid="j_jtim-2023-0122_ref_065" ref-type="bibr">65</xref>]</sup> The m6A modification is preferable to viral IRESs when considering construct size.<sup>[<xref rid="j_jtim-2023-0122_ref_079" ref-type="bibr">79</xref>]</sup> However, the two strategies can be combined. For example, m6A increases the effectiveness of circZNF609 translation mediated by IRES. <sup>[<xref rid="j_jtim-2023-0122_ref_053" ref-type="bibr">53</xref>,<xref rid="j_jtim-2023-0122_ref_080" ref-type="bibr">80</xref>]</sup> Moreover, a recent study improved circRNA translation. According to Chen et al., the optimization of these five elements&#x02014;5&#x02019; and 3&#x02019; UTRs, vector topology, synthetic aptamers, and IRESs&#x02014;can not only lead to an increase in protein yields of circRNA by several hundred folds but also enable powerful, long-lasting protein production <italic toggle="yes">in vivo</italic>.<sup>[<xref rid="j_jtim-2023-0122_ref_066" ref-type="bibr">66</xref>]</sup></p></sec><sec id="j_jtim-2023-0122_s_004_s_002"><title>Synthesis of precursor linear RNA</title><p>There are two methods for synthesizing the precursor linear RNAs for circRNA synthesis: chemical and enzymatic.<sup>[<xref rid="j_jtim-2023-0122_ref_081" ref-type="bibr">81</xref>,<xref rid="j_jtim-2023-0122_ref_082" ref-type="bibr">82</xref>]</sup> Techniques for RNA chemical synthesis depend on synthesizer machines. Phosphoramidites, derivatives of nucleotide triphosphates, are used in the procedure as fundamental components of linear oligonucleotides.<sup>[<xref rid="j_jtim-2023-0122_ref_079" ref-type="bibr">79</xref>]</sup> Phage RNA polymerases are used in enzymatic strategies for IVT. An IVT reaction is usually conducted using the following main components: a double-stranded DNA template, ribonucleotide triphosphates, and DNA-dependent RNA polymerase.<sup>[<xref rid="j_jtim-2023-0122_ref_079" ref-type="bibr">79</xref>]</sup></p></sec><sec id="j_jtim-2023-0122_s_004_s_003"><title>RNA circularization in vitro</title><p>Generally, exogenous RNA circularization can be achieved using three strategies: chemically, using cyanogen bromide or a similar condensing agent; enzymatically, using DNA or RNA ligases; or ribozymatically, using self-splicing introns.<sup>[<xref rid="j_jtim-2023-0122_ref_069" ref-type="bibr">69</xref>]</sup></p></sec><sec id="j_jtim-2023-0122_s_004_s_004"><title>Chemical strategies</title><p>The most commonly used approach is applying 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide or the condensation reagent cyanogen bromide to activate RNA circularization.<sup>[<xref rid="j_jtim-2023-0122_ref_083" ref-type="bibr">83</xref>]</sup> Additional chemical methods rely on replacing native phosphate and hydroxyl groups of linear RNA with other functional groups. These alternative reactive groups help form bonds with excellent selectivity and efficacy, increasing the purity and quantities of circularized RNA.<sup>[<xref rid="j_jtim-2023-0122_ref_084" ref-type="bibr">84</xref>]</sup></p></sec><sec id="j_jtim-2023-0122_s_004_s_005"><title>Enzymatic strategies</title><p>Three types of polynucleotide ligases are commonly used in the enzymatic ligation of synthetic oligonucleotides: T4 RNA ligase 1, T4 DNA ligase, and T4 RNA ligase 2. They are encoded in the genome of the bacteriophage T4 and can ligate nicks in single-and/or double-stranded RNA constructs. <sup>[<xref rid="j_jtim-2023-0122_ref_085" ref-type="bibr">85</xref>,<xref rid="j_jtim-2023-0122_ref_086" ref-type="bibr">86</xref>]</sup> They assist in the circularization process by promoting the ATP-consuming synthesis of a phosphodiester bond between the 3&#x02032;-hydroxyl (acceptor) and 5&#x02032;-phosphate (donor) end groups in RNA or DNA.<sup>[<xref rid="j_jtim-2023-0122_ref_087" ref-type="bibr">87</xref>]</sup></p></sec><sec id="j_jtim-2023-0122_s_004_s_006"><title>Ribozymatic strategies</title><p>Ribozymatic strategies are the most commonly used methods for RNA circularization, particularly when the production of large circular RNAs is required.<sup>[<xref rid="j_jtim-2023-0122_ref_088" ref-type="bibr">88</xref>]</sup> Group I and group II introns play a role in circRNA production <italic toggle="yes">in vitro</italic>.<sup>[<xref rid="j_jtim-2023-0122_ref_089" ref-type="bibr">89</xref>, <xref rid="j_jtim-2023-0122_ref_090" ref-type="bibr">90</xref>, <xref rid="j_jtim-2023-0122_ref_091" ref-type="bibr">91</xref>]</sup> However, the use of group I introns is more common than that of group II. In 1992, Puttaraju and Been reported the first use of the group I intron system to synthesize circRNAs from a linear precursor containing introns. The Anabaena pre-tRNA<sup>Leu</sup> gene was used to form a PIE construct, in which the 5&#x02032;half of the group I tRNA intron was moved to the tail of the tRNA exon, the remaining 3&#x02032;half of the intron was placed at the head of the same exon, and circRNAs were formed through exon ligation.<sup>[<xref rid="j_jtim-2023-0122_ref_092" ref-type="bibr">92</xref>]</sup> The <italic toggle="yes">in vitro</italic> circularization of RNAs can be achieved more efficiently than by using the aforementioned method by using group II introns and does not require native exons.<sup>[<xref rid="j_jtim-2023-0122_ref_089" ref-type="bibr">89</xref>]</sup> In this pathway, the circularized exon and the excised group II intron are joined together by 3&#x02032;-5&#x02032; and 2&#x02032;-5&#x02032; phosphodiester linkages separately. However, the exact mechanism underlying this process remains unclear.<sup>[<xref rid="j_jtim-2023-0122_ref_093" ref-type="bibr">93</xref>]</sup></p></sec></sec><sec id="j_jtim-2023-0122_s_005"><title>Delivery of circRNA vaccine</title><p>The goal of a vaccine is not only to elicit an initial response to specific antigens but also to promote an enduring response from the body&#x02019;s adaptive immune system.<sup>[<xref rid="j_jtim-2023-0122_ref_094" ref-type="bibr">94</xref>]</sup> By exposing the immune system to a particular antigen (or antigens), a vaccine can generate long-lived protective immunity in the form of memory T cells, memory B cells, and antibody-producing plasma cells.<sup>[<xref rid="j_jtim-2023-0122_ref_095" ref-type="bibr">95</xref>]</sup> Appropriate vaccine delivery is vital to guarantee successful vaccination.</p><p>CircRNAs function by producing specific antigens in the host&#x02019;s cytoplasm. However, they are too large to diffuse freely across cell membranes. CircRNAs might benefit from RNA delivery mechanisms already present, and their distinct structural features might help with formulation and distribution. The terminus-free structure of circRNAs enables resistance to exonuclease degradation, making them suitable for carrier-free administration.<sup>[<xref rid="j_jtim-2023-0122_ref_096" ref-type="bibr">96</xref>]</sup> For example, naked cmRNA dissolved in PBS was directly injected into the tumor tissues of four types of tumor models, resulting in the detection of its specific expression product.<sup>[<xref rid="j_jtim-2023-0122_ref_070" ref-type="bibr">70</xref>]</sup> The literature demonstrated that conventional physical techniques such as gene guns, electroporation, and microneedles improved the efficacy of naked mRNA antigen presentation.<sup>[<xref rid="j_jtim-2023-0122_ref_097" ref-type="bibr">97</xref>]</sup> These results imply that the same methods can be used to facilitate the administration of naked circRNA vaccines. CircRNAs can be delivered to carriers such as nanoparticles. Among all mRNA delivery vehicles, the lipid-based nanoparticle delivery system is the most efficient and occupies the leading status.<sup>[<xref rid="j_jtim-2023-0122_ref_098" ref-type="bibr">98</xref>]</sup> Its advantages include biocompatibility, ease of formation, modularity, and substantial payload capacity.<sup>[<xref rid="j_jtim-2023-0122_ref_099" ref-type="bibr">99</xref>]</sup> Moreover, the relatively compact structure of circRNAs may contribute to their high loading capacity into RNA delivery carriers such as viral carriers or nanoparticles.<sup>[<xref rid="j_jtim-2023-0122_ref_020" ref-type="bibr">20</xref>]</sup> In improving their efficiency, circRNAs are often administered <italic toggle="yes">via</italic> nanocarriers. For instance, purified hEpo circRNAs encased in LNPs demonstrated robust expression when injected into 293 cells, demonstrating the potency of <italic toggle="yes">in vivo</italic> circRNA delivery <italic toggle="yes">via</italic> lipid nanoparticles.<sup>[<xref rid="j_jtim-2023-0122_ref_100" ref-type="bibr">100</xref>]</sup> Although researchers have managed to deliver functional circRNAs in naked and carrier-facilitated forms, the use of RNA delivery carriers, especially nanoparticles, is a more commonly used method for vaccine delivery.</p><p>Immune reactivity after vaccine injection is a key factor affecting vaccine function. The immune response begins as soon as the circRNA reaches the cytoplasm. In this study, we used an LNP-encapsulated circRNA vaccine. After the injection of a circRNA vaccine, circRNA-LNPs are taken up by cells through fusion with the endosomal membrane. Next, circRNAs are translated into proteins by ribosomes after they enter the cytosol. These antigens can trigger immune responses as follows <sup>[<xref rid="j_jtim-2023-0122_ref_101" ref-type="bibr">101</xref>]</sup>: (1) The proteasome complex breaks down intracellular antigens into smaller molecules, which are then displayed on the cell surface of CD8<sup>+</sup> T cells <italic toggle="yes">via</italic> attachment to MHC I (MHC I is present on the surface of almost all nucleated cells). T lymphocytes are activated and prepare to provoke a cellular immune response when they recognize and attach to epitope-bound MHC I receptors. Once activated, cytotoxic T cells excrete cytokines such as TNF&#x003b1; and IFN-&#x003b3;, as well as cytolytic molecules, such as perforin and granzyme. Proteases can enter targeted cells through the cell membrane pores created by these cytotoxic chemicals, initiate viral protein degradation, and bolster cellular apoptosis. (2) Secreted antigens can be absorbed by antigen-presenting cells (APCs), broken down inside endosomes, and displayed on the cell surface by MHC class II proteins. When the APC is a B lymphocyte, it can develop into a plasma cell and release IgM antibodies. When a CD4<sup>+</sup> T cell interacts with the APC, the CD4<sup>+</sup> T cell becomes activated; facilitates the activation of phagocytes; and advocates B cell proliferation, as well as somatic hypermutation. This procedure generates antibody variants with high antigen affinities to yield highly efficient and specific immune responses. These B cells can either be retained as memory B cells or distributed in the bloodstream as plasma cells that secrete IgG antibodies. The APC can travel to the body&#x02019;s lymph nodes, participate in T cell-dependent B cell maturation, and aid in the development of a more potent and persistent humoral immune response against the vaccine antigen <sup>[<xref rid="j_jtim-2023-0122_ref_099" ref-type="bibr">99</xref>, <xref rid="j_jtim-2023-0122_ref_102" ref-type="bibr">102</xref>]</sup> (<xref rid="j_jtim-2023-0122_fig_001" ref-type="fig">Figure 1</xref>).</p><fig position="float" id="j_jtim-2023-0122_fig_001" fig-type="figure"><label>Figure 1</label><caption><p>CircRNA <italic toggle="yes">in vivo</italic> delivery and immunity activation. A circRNA vaccine is administered <italic toggle="yes">via</italic> the intramuscular route into the deltoid. circRNA-LNPs are taken up by an APC (antigen-presenting cell) through fusion with the endosomal membrane. CircRNAs combine with ribosomes and are translated into antigen proteins. The intracellular antigen is broken down into smaller fragments by the proteasome complex, and the fragments are displayed on the cell surface to cytotoxic T cells (CD8<sup>+</sup> T cells) via attachment to MHC I (MHC I is expressed on the surface of nucleated bodily cells). Cytotoxic T cells (CD8<sup>+</sup> T cells) become activated through recognition and binding to the epitope-bound MHC I receptor, secreting cytokines and cytolytic molecules and thus initiating the cellular immune response. Translated antigen proteins can be secreted outside the cell. These secreted antigens can activate a B cell through BCR (B cell receptor) and make it transform into a plasma cell that secretes IgM antibodies. They can also be taken up by APCs, degraded inside endosomes, and presented on the cell surface by MHC class II proteins. When a CD4<sup>+</sup> T cell interacts with the APC, it becomes activated and facilitates the activation of macrophages and somatic hypermutation within B cells. These B cells can either be stored as memory cells or disseminate into the blood as plasma cells secreting IgG antibodies.</p></caption><graphic xlink:href="j_jtim-2023-0122_fig_001" position="float"/></fig></sec><sec id="j_jtim-2023-0122_s_006"><title>Current circRNA vaccines</title><sec id="j_jtim-2023-0122_s_006_s_001"><title>Viral infectious disease</title><sec id="j_jtim-2023-0122_s_006_s_001_s_001"><title>CircRNA<sup>RBD</sup>: SARS-CoV-2 receptor-binding domain (RBD) encoding circRNA vaccine</title><p>In this study, Qu L and colleagues synthesized a circRNA vaccine that encoded SARS-CoV-2 RBD antigens by using both ribozymatic and enzymatic strategies in RNA circularization (described by Wesselhoeft <italic toggle="yes">et al</italic>.) and encapsulated the circRNAs with LNPs. circRNA-encoded RBD antigens are also functional. Mice (female BALB/c mice aged 6&#x02013;8 weeks) and rhesus macaques (male, aged 2&#x02013;4 years) effectively elicited sufficient neutralizing antibodies and potent specific T cell responses against SARS-CoV-2. Moreover, compared with its mRNA counterpart, this circRNA vaccine induced larger quantities of immunogens that were more durable and evoked a greater median proportion of protective antibodies against SARS-CoV-2 and their emerging variants, such as Omicron and Delta and Th1-skewed immune responses. In addition, the study proved that the delta-specific vaccine circRNA<sup>RBD-Delta</sup> could provide cross-protection against all other variants, including Omicron, and could serve as an efficient booster after two doses of the initial SARS-CoV-2 vaccination. CircRNAs that encode SARS-CoV-2-specific neutralizing nanobodies, as well as hACE2 decoys, were also tested for their therapeutic potential and were effective in neutralizing SARS-CoV-2 pseudovirus. Furthermore, in vaccinated nonhuman primates, the circRNA vaccine did not cause clinical signs of sickness or exacerbated pathology, which may be proof of its safety.<sup>[<xref rid="j_jtim-2023-0122_ref_071" ref-type="bibr">71</xref>]</sup></p></sec></sec><sec id="j_jtim-2023-0122_s_006_s_002"><title>VFLIP-X: a SARS-CoV-2 circRNA vaccine</title><p>In the present study, VFLIP-X, a circRNA vaccine targeting SARS-CoV-2, was developed to test its potential as a new-generation COVID-19 vaccine. For the <italic toggle="yes">in vivo</italic> experiments to test the validity of this vaccine, 7-week-old female BALB/C mice were used. VFLIP is a spike protein engineered using one flexible S1/S2 linker, five proline replacements in the S2 subunit, and two cysteine substitutions to induce intermolecular disulfide bond formation. VFLIP-X contains six reasonably replaced amino acids rationally chosen based on the co-mutation (D614G) discovered in all SARS-CoV-2 variants and five mutations (E484K, K417N, L452R, N501Y, and T478K) co-identified in multiple variants of concern and variants of interest. The circRNAs were produced by T7 RNA polymerase-based <italic toggle="yes">in vitro</italic> transcription and encapsulated in LNPs. According to the research, VFLIP-X imparts neutralization against SARS-CoV-2, stimulates the generation of cross-neutralizing antibodies against SARS-CoV-2 variants, and activates humoral and cellular immune responses against B. 1.1.529 variant. This study identified that a SARS-CoV-2 circRNA vaccine encoding a relatively stable VFLIP-X spike immunogen would be suitable as a next-generation COVID-19 vaccine guarding against existing and developing SARS-CoV-2 variants.<sup>[<xref rid="j_jtim-2023-0122_ref_103" ref-type="bibr">103</xref>]</sup></p></sec><sec id="j_jtim-2023-0122_s_006_s_003"><title>Tumor immune therapy</title><sec id="j_jtim-2023-0122_s_006_s_003_s_001"><title>Cytokine-encoding circular mRNA for cancer therapy</title><p>An innovative form of circular mRNA, named cmRNA, was developed in the study. It is produced using the PIE system, which utilizes a novel spacer1 and E29 IRES to guide protein translation and is encapsulated in LNPs. This type of circular mRNA is more resilient than linear mRNA and can mediate a larger amount of protein production than linear mRNA can. Tumor cells and mouse models were used for the <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> experiments, respectively. The <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> experiments confirmed its ability to efficiently express various proteins, suggesting its use as a universal vector for protein expression. Intratumoral injection of a cmRNA compound encoding four cytokines induced a significant tumor-repressive effect. It activates immune cells, especially T cells, and collaborates with anti-PD-1 antibodies to promote total immune cell penetration into the tumor, exerting a strong antitumor effect. These results indicate that this novel type of naked cmRNA has the potential to serve as an RNA platform for the development of various intratumoral therapies.<sup>[<xref rid="j_jtim-2023-0122_ref_070" ref-type="bibr">70</xref>]</sup></p></sec></sec><sec id="j_jtim-2023-0122_s_006_s_004"><title>CircRNA<sup>OVA-luc</sup>-LNP vaccine</title><p>A circRNA<sup>OVA-luc</sup>-LNP (OVA[257-264]-luciferase-coding circRNA) vaccine was constructed using the PIE system and encapsulated in LNPs. Three mouse tumor models were established to evaluate the efficacy of the vaccine. circRNAs demonstrate better stability and trigger longer-lasting protein expression. circRNA-LNPs elicited a potent innate immunological response and a remarkable antigen-specific response. This circRNA-LNP vaccine has shown great efficacy in suppressing the advancement of immune-exclusive tumors, inducing complete tumor regression in immunological desert tumors, and preventing cancer cell metastasis. In addition, circRNA-LNPs can collaborate with adoptive cell transfer therapy and completely repress the progression of late-stage immune-exclusive tumors by reinforcing the persistence of TCR-T cells, demonstrating the potential of RNA vaccines as tumor therapeutics.<sup>[<xref rid="j_jtim-2023-0122_ref_104" ref-type="bibr">104</xref>]</sup></p><p>As shown in <xref rid="j_jtim-2023-0122_tab_001" ref-type="table">Table 1</xref>, the characteristics of the circRNA vaccine, including its high stability, efficacy in protein expression, stable and durable expression products, and ability to initiate immune responses, are why it is an attractive alternative to the aforementioned vaccines. Additionally, circRNA vaccines are superior to mRNA vaccines. Moreover, its manufacturing procedures and preservation conditions are simple and economical, making it more suitable for mass production and wide applications.</p><table-wrap position="float" id="j_jtim-2023-0122_tab_001"><label>Table 1</label><caption><p>Comparison of the emerging circRNA vaccines</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Vaccine</th><th align="left" rowspan="1" colspan="1">Target immunogen</th><th align="left" rowspan="1" colspan="1">RNA circularization strategy</th><th align="left" rowspan="1" colspan="1">Delivery method</th><th align="left" rowspan="1" colspan="1">Structure to initiate translation</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">circRNA<sup>RBD</sup></td><td align="left" rowspan="1" colspan="1">SARS-CoV-2 RBD (receptor- binding domain) antigen</td><td align="left" rowspan="1" colspan="1">Enzymatic and ribozymatic (T4 RNA (group ligase) I intron autocatalysis strategy)</td><td align="left" rowspan="1" colspan="1">LNP</td><td align="left" rowspan="1" colspan="1">CVB3 IRES</td></tr><tr><td align="left" rowspan="1" colspan="1">VFLIP-X</td><td align="left" rowspan="1" colspan="1">SARS-VFLIP-CoV-X 2 spike protein</td><td align="left" rowspan="1" colspan="1">Enzymatic (T4 RNA ligase)</td><td align="left" rowspan="1" colspan="1">LNP</td><td align="left" rowspan="1" colspan="1">CVB3 IRES</td></tr><tr><td align="left" rowspan="1" colspan="1">Cytokine-encoding circular mRNA</td><td align="left" rowspan="1" colspan="1">4 cytokines (active IL-15, IL- 12sc, GM-CSF, IFN-a 2b)</td><td align="left" rowspan="1" colspan="1">Ribozymatic (group I intron autocatalysis strategy)</td><td align="left" rowspan="1" colspan="1">LNP</td><td align="left" rowspan="1" colspan="1">E29 IRES</td></tr><tr><td align="left" rowspan="1" colspan="1">circRNA<sup>OVA-luc</sup>-LNP</td><td align="left" rowspan="1" colspan="1">OVA (257&#x02013;264)-luciferase</td><td align="left" rowspan="1" colspan="1">Ribozymatic autocatalysis (group strategy) I intron</td><td align="left" rowspan="1" colspan="1">LNP</td><td align="left" rowspan="1" colspan="1">CVB3 IRES</td></tr></tbody></table></table-wrap></sec></sec><sec id="j_jtim-2023-0122_s_007"><title>Conclusions</title><p>Owing to the many advantages of circRNA, for example, high stability and achievable high translation efficiency, we used it as a vaccine. However, additional studies and improvements are required before circRNA vaccination becomes widely available. The literature has shown that circRNA vaccines do not lead to clinical signs of sickness, and further investigation is required to determine the safety of circRNA vaccines. Moreover, the impact of circRNA immunogenicity on vaccine development, which may act as an inhibitor of vaccine development, remains unclear. The classical methods described by Wesselhoeft <italic toggle="yes">et al</italic>. have been adopted and successfully used in the literature aiming to generate circRNA vaccines. However, limitations persist in the current circRNA synthesis techniques, such as low circularization productivity and the high expense of reagents such as enzymes. The stage of the current production strategies and facilities is too immature to produce massive quantities, which is an important factor restricting the application of circRNA vaccines (<xref rid="j_jtim-2023-0122_fig_002" ref-type="fig">Figure 2</xref>). With future technological advances, we envision a broad application of circRNA vaccines in clinical trials to prevent infectious diseases and suppress tumor malignancies.</p><fig position="float" id="j_jtim-2023-0122_fig_002" fig-type="figure"><label>Figure 2</label><caption><p>Advantages and disadvantages of circRNA vaccine.</p></caption><graphic xlink:href="j_jtim-2023-0122_fig_002" position="float"/></fig></sec></body><back><fn-group><fn fn-type="other" id="j_jtim-2023-0122_fn_001"><p>
<bold>Author Contributions</bold>
</p><p>Research design: Yutian Zou and Shaoquan Zheng; data collection: Jindong Xie and Fengxi Ye; data analysis: Jindong Xie, Fengxi Ye, and Xinpei Deng; manuscript preparation: Jindong Xie, Fengxi Ye, Xinpei Deng, Yuhui Tang, Jie-Ying Liang, Xufeng Huang, Yuying Sun, Hailin Tang, and Jinsong Lei; manuscript editing: Yutian Zou and Shaoquan Zheng. All authors confirm that they contributed to manuscript reviews and critical revision for important intellectual content and read and approved the final draft for submission. All authors agree to be accountable for the contents of the study. All the authors have read and agreed to the published version of the manuscript.</p></fn><fn fn-type="COI-statement" id="j_jtim-2023-0122_fn_002"><p>
<bold>Conflicts of Interest</bold>
</p><p>The authors declare no conflict of interest.</p></fn></fn-group><ref-list><title>References</title><ref id="j_jtim-2023-0122_ref_001"><label>1</label><element-citation publication-type="journal"><name><surname>Meyer</surname><given-names>H</given-names></name><name><surname>Ehmann</surname><given-names>R</given-names></name><name><surname>Smith</surname><given-names>GL</given-names></name><article-title>Smallpox in the Post-Eradication Era</article-title><source>Viruses</source><year>2020</year><volume>12</volume><fpage>138</fpage><pub-id pub-id-type="pmid">31991671</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_002"><label>2</label><element-citation publication-type="journal"><name><surname>Francis</surname><given-names>MJ</given-names></name><article-title>Recent Advances in Vaccine Technologies</article-title><source>Vet Clin North Am Small Anim Pract</source><year>2018</year><volume>48</volume><fpage>231</fpage><comment>&#x02013;</comment><lpage>241</lpage><pub-id pub-id-type="pmid">29217317</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_003"><label>3</label><element-citation publication-type="journal"><name><surname>Plotkin</surname><given-names>SA</given-names></name><name><surname>Plotkin</surname><given-names>SL</given-names></name><article-title>The development of vaccines: how the past led to the future</article-title><source>Nat Rev Microbiol</source><year>2011</year><volume>9</volume><fpage>889</fpage><comment>&#x02013;</comment><lpage>893</lpage><pub-id pub-id-type="pmid">21963800</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_004"><label>4</label><element-citation publication-type="journal"><name><surname>Soni</surname><given-names>D</given-names></name><name><surname>Van</surname><given-names>Haren SD</given-names></name><name><surname>Idoko</surname><given-names>OT</given-names></name><name><surname>Evans</surname><given-names>JT</given-names></name><name><surname>Diray-Arce</surname><given-names>J</given-names></name><name><surname>Dowling</surname><given-names>DJ</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Towards Precision Vaccines: Lessons From the Second International Precision Vaccines Conference</article-title><source>Front Immunol</source><year>2020</year><volume>11</volume><fpage>590373</fpage><pub-id pub-id-type="pmid">33178222</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_005"><label>5</label><element-citation publication-type="journal"><name><surname>Polack</surname><given-names>FP</given-names></name><name><surname>Thomas</surname><given-names>SJ</given-names></name><name><surname>Kitchin</surname><given-names>N</given-names></name><name><surname>Absalon</surname><given-names>J</given-names></name><name><surname>Gurtman</surname><given-names>A</given-names></name><name><surname>Lockhart</surname><given-names>S</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine</article-title><source>N Engl J Med</source><year>2020</year><volume>383</volume><fpage>2603</fpage><comment>&#x02013;</comment><lpage>2615</lpage><pub-id pub-id-type="pmid">33301246</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_006"><label>6</label><element-citation publication-type="journal"><name><surname>Mulligan</surname><given-names>MJ</given-names></name><name><surname>Lyke</surname><given-names>KE</given-names></name><name><surname>Kitchin</surname><given-names>N</given-names></name><name><surname>Absalon</surname><given-names>J</given-names></name><name><surname>Gurtman</surname><given-names>A</given-names></name><name><surname>Lockhart</surname><given-names>S</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Publisher Correction: Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults.</article-title><source>Nature</source><year>2021</year><comment>Feb</comment><volume>590</volume><issue>7844</issue><fpage>E26</fpage><comment>doi</comment><pub-id pub-id-type="doi">10.1038/s41586-020-03098-3.</pub-id><comment>Erratum for: Nature 2020;586:589-593</comment><pub-id pub-id-type="pmid">33469216</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_007"><label>7</label><element-citation publication-type="journal"><name><surname>Voysey</surname><given-names>M</given-names></name><name><surname>Clemens</surname><given-names>SAC</given-names></name><name><surname>Madhi</surname><given-names>SA</given-names></name><name><surname>Weckx</surname><given-names>LY</given-names></name><name><surname>Folegatti</surname><given-names>PM</given-names></name><name><surname>Aley</surname><given-names>PK</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Safety and efficacy of the ChAdOx1 nCoV- 19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK</article-title><source>Lancet</source><year>2021</year><volume>397</volume><fpage>99</fpage><comment>&#x02013;</comment><lpage>111</lpage><pub-id pub-id-type="pmid">33306989</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_008"><label>8</label><element-citation publication-type="journal"><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Jie</surname><given-names>Z</given-names></name><article-title>Delta Variant: Partially Sensitive To Vaccination, but Still Worth Global Attention</article-title><source>J Transl Int Med</source><year>2022</year><volume>10</volume><fpage>227</fpage><comment>&#x02013;</comment><lpage>235</lpage><pub-id pub-id-type="pmid">36776232</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_009"><label>9</label><element-citation publication-type="journal"><name><surname>Vasileiou</surname><given-names>E</given-names></name><name><surname>Simpson</surname><given-names>CR</given-names></name><name><surname>Shi</surname><given-names>T</given-names></name><name><surname>Kerr</surname><given-names>S</given-names></name><name><surname>Agrawal</surname><given-names>U</given-names></name><name><surname>Akbari</surname><given-names>A</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study</article-title><source>Lancet</source><year>2021</year><volume>397</volume><fpage>1646</fpage><comment>&#x02013;</comment><lpage>1657</lpage><pub-id pub-id-type="pmid">33901420</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_010"><label>10</label><element-citation publication-type="journal"><name><surname>Lopez</surname><given-names>Bernal J</given-names></name><name><surname>Andrews</surname><given-names>N</given-names></name><name><surname>Gower</surname><given-names>C</given-names></name><name><surname>Gallagher</surname><given-names>E</given-names></name><name><surname>Simmons</surname><given-names>R</given-names></name><name><surname>Thelwall</surname><given-names>S</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Effectiveness of Covid- 19 Vaccines against the B.1.617.2 (Delta) Variant</article-title><source>N Engl J Med</source><year>2021</year><volume>385</volume><fpage>585</fpage><comment>&#x02013;</comment><lpage>594</lpage><pub-id pub-id-type="pmid">34289274</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_011"><label>11</label><element-citation publication-type="journal"><name><surname>Jeck</surname><given-names>WR</given-names></name><name><surname>Sharpless</surname><given-names>NE</given-names></name><article-title>Detecting and characterizing circular RNAs</article-title><source>Nat Biotechnol</source><year>2014</year><volume>32</volume><fpage>453</fpage><comment>&#x02013;</comment><lpage>461</lpage><pub-id pub-id-type="pmid">24811520</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_012"><label>12</label><element-citation publication-type="journal"><name><surname>Zhou</surname><given-names>WY</given-names></name><name><surname>Cai</surname><given-names>ZR</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>DS</given-names></name><name><surname>Ju</surname><given-names>HQ</given-names></name><name><surname>Xu</surname><given-names>RH</given-names></name><article-title>Circular RNA: metabolism, functions and interactions with proteins</article-title><source>Mol Cancer</source><year>2020</year><volume>19</volume><fpage>172</fpage><pub-id pub-id-type="pmid">33317550</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_013"><label>13</label><element-citation publication-type="journal"><name><surname>Salzman</surname><given-names>J</given-names></name><name><surname>Gawad</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>PL</given-names></name><name><surname>Lacayo</surname><given-names>N</given-names></name><name><surname>Brown</surname><given-names>PO</given-names></name><article-title>Circular RNAs are the predominant transcript isoform from hundreds of human genes in diverse cell types</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><fpage>e30733</fpage><pub-id pub-id-type="pmid">22319583</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_014"><label>14</label><element-citation publication-type="journal"><name><surname>Szabo</surname><given-names>L</given-names></name><name><surname>Salzman</surname><given-names>J</given-names></name><article-title>Detecting circular RNAs: bioinformatic and experimental challenges</article-title><source>Nat Rev Genet</source><year>2016</year><volume>17</volume><fpage>679</fpage><comment>&#x02013;</comment><lpage>692</lpage><pub-id pub-id-type="pmid">27739534</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_015"><label>15</label><element-citation publication-type="journal"><name><surname>Zeng</surname><given-names>Y</given-names></name><name><surname>Zou</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>G</given-names></name><name><surname>Zheng</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Xie</surname><given-names>X</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>The biogenesis, function and clinical significance of circular RNAs in breast cancer</article-title><source>Cancer Biol Med</source><year>2021</year><volume>19</volume><fpage>14</fpage><pub-id pub-id-type="pmid">34110722</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_016"><label>16</label><element-citation publication-type="journal"><name><surname>Nigro</surname><given-names>JM</given-names></name><name><surname>Cho</surname><given-names>KR</given-names></name><name><surname>Fearon</surname><given-names>ER</given-names></name><name><surname>Kern</surname><given-names>SE</given-names></name><name><surname>Ruppert</surname><given-names>JM</given-names></name><name><surname>Oliner</surname><given-names>JD</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Scrambled exons</article-title><source>Cell</source><year>1991</year><volume>64</volume><fpage>607</fpage><comment>&#x02013;</comment><lpage>613</lpage><pub-id pub-id-type="pmid">1991322</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_017"><label>17</label><element-citation publication-type="journal"><name><surname>Huang</surname><given-names>A</given-names></name><name><surname>Zheng</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><article-title>Circular RNA-protein interactions: functions, mechanisms, and identification.</article-title><source>Theranostics</source><year>2020</year><volume>10</volume><fpage>3503</fpage><comment>-</comment><lpage>3517</lpage><pub-id pub-id-type="pmid">32206104</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_018"><label>18</label><element-citation publication-type="journal"><name><surname>Salzman</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>RE</given-names></name><name><surname>Olsen</surname><given-names>MN</given-names></name><name><surname>Wang</surname><given-names>PL</given-names></name><name><surname>Brown</surname><given-names>PO</given-names></name><article-title>Cell-type specific features of circular RNA expression</article-title><source>PLoS Genet</source><year>2013</year><volume>9</volume><fpage>e1003777</fpage><pub-id pub-id-type="pmid">24039610</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_019"><label>19</label><element-citation publication-type="journal"><name><surname>Liu</surname><given-names>A</given-names></name><name><surname>Jiang</surname><given-names>B</given-names></name><name><surname>Song</surname><given-names>C</given-names></name><name><surname>Zhong</surname><given-names>Q</given-names></name><name><surname>Mo</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>R</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Isoliquiritigenin inhibits circ0030018 to suppress glioma tumorigenesis via the miR-1236/HER2 signaling pathway</article-title><source>MedComm</source><year>2020</year><comment>2023</comment><volume>4</volume><fpage>e282</fpage></element-citation></ref><ref id="j_jtim-2023-0122_ref_020"><label>20</label><element-citation publication-type="journal"><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>S</given-names></name><name><surname>Dain</surname><given-names>L</given-names></name><name><surname>Mei</surname><given-names>L</given-names></name><name><surname>Zhu</surname><given-names>G</given-names></name><article-title>Circular RNA: An emerging frontier in RNA therapeutic targets, RNA therapeutics, and mRNA vaccines</article-title><source>J Control Release</source><year>2022</year><volume>348</volume><fpage>84</fpage><comment>&#x02013;</comment><lpage>94</lpage><pub-id pub-id-type="pmid">35649485</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_021"><label>21</label><element-citation publication-type="journal"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Issaian</surname><given-names>A</given-names></name><name><surname>Hill</surname><given-names>RC</given-names></name><name><surname>Espinosa</surname><given-names>S</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>A unified mechanism for intron and exon definition and back-splicing</article-title><source>Nature</source><year>2019</year><volume>573</volume><fpage>375</fpage><comment>&#x02013;</comment><lpage>380</lpage><pub-id pub-id-type="pmid">31485080</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_022"><label>22</label><element-citation publication-type="journal"><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Shen</surname><given-names>Z</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Landscape of cell heterogeneity and evolutionary trajectory in ulcerative colitis-associated colon cancer revealed by single-cell RNA sequencing</article-title><source>Chin J Cancer Res</source><year>2021</year><volume>33</volume><fpage>271</fpage><comment>-</comment><lpage>288</lpage><pub-id pub-id-type="pmid">34158745</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_023"><label>23</label><element-citation publication-type="journal"><name><surname>Lu</surname><given-names>Z</given-names></name><name><surname>Filonov</surname><given-names>GS</given-names></name><name><surname>Noto</surname><given-names>JJ</given-names></name><name><surname>Schmidt</surname><given-names>CA</given-names></name><name><surname>Hatkevich</surname><given-names>TL</given-names></name><name><surname>Wen</surname><given-names>Y</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Metazoan tRNA introns generate stable circular RNAs in vivo</article-title><source>RNA</source><year>2015</year><volume>21</volume><fpage>1554</fpage><comment>&#x02013;</comment><lpage>1565</lpage><pub-id pub-id-type="pmid">26194134</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_024"><label>24</label><element-citation publication-type="journal"><name><surname>Danan</surname><given-names>M</given-names></name><name><surname>Schwartz</surname><given-names>S</given-names></name><name><surname>Edelheit</surname><given-names>S</given-names></name><name><surname>Sorek</surname><given-names>R</given-names></name><article-title>Transcriptome-wide discovery of circular RNAs in Archaea</article-title><source>Nucleic Acids Res</source><year>2012</year><volume>40</volume><fpage>3131</fpage><comment>&#x02013;</comment><lpage>3142</lpage><pub-id pub-id-type="pmid">22140119</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_025"><label>25</label><element-citation publication-type="journal"><name><surname>Kristensen</surname><given-names>LS</given-names></name><name><surname>Andersen</surname><given-names>MS</given-names></name><name><surname>Stagsted</surname><given-names>LVW</given-names></name><name><surname>Ebbesen</surname><given-names>KK</given-names></name><name><surname>Hansen</surname><given-names>TB</given-names></name><name><surname>Kjems</surname><given-names>J</given-names></name><article-title>The biogenesis, biology and characterization of circular RNAs</article-title><source>Nat Rev Genet</source><year>2019</year><volume>20</volume><fpage>675</fpage><comment>&#x02013;</comment><lpage>691</lpage><pub-id pub-id-type="pmid">31395983</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_026"><label>26</label><element-citation publication-type="journal"><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Wilusz</surname><given-names>JE</given-names></name><name><surname>Chen</surname><given-names>LL</given-names></name><article-title>Biogenesis and Regulatory Roles of Circular RNAs</article-title><source>Annu Rev Cell Dev Biol</source><year>2022</year><volume>38</volume><fpage>263</fpage><comment>&#x02013;</comment><lpage>289</lpage><pub-id pub-id-type="pmid">35609906</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_027"><label>27</label><element-citation publication-type="journal"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>LL</given-names></name><article-title>The biogenesis, functions, and challenges of circular RNAs.</article-title><source>Mol Cell</source><year>2018</year><volume>71</volume><issue>3</issue><fpage>428</fpage><comment>&#x02013;</comment><lpage>42</lpage><pub-id pub-id-type="pmid">30057200</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_028"><label>28</label><element-citation publication-type="journal"><name><surname>Starke</surname><given-names>S</given-names></name><name><surname>Jost</surname><given-names>I</given-names></name><name><surname>Rossbach</surname><given-names>O</given-names></name><name><surname>Schneider</surname><given-names>T</given-names></name><name><surname>Schreiner</surname><given-names>S</given-names></name><name><surname>Hung</surname><given-names>LH</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Exon circularization requires canonical splice signals</article-title><source>Cell Rep</source><year>2015</year><volume>10</volume><fpage>103</fpage><comment>&#x02013;</comment><lpage>111</lpage><pub-id pub-id-type="pmid">25543144</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_029"><label>29</label><element-citation publication-type="journal"><name><surname>Ashwal-Fluss</surname><given-names>R</given-names></name><name><surname>Meyer</surname><given-names>M</given-names></name><name><surname>Pamudurti</surname><given-names>NR</given-names></name><name><surname>Ivanov</surname><given-names>A</given-names></name><name><surname>Bartok</surname><given-names>O</given-names></name><name><surname>Hanan</surname><given-names>M</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>circRNA biogenesis competes with pre-mRNA splicing</article-title><source>Mol Cell</source><year>2014</year><volume>56</volume><fpage>55</fpage><comment>&#x02013;</comment><lpage>66</lpage><pub-id pub-id-type="pmid">25242144</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_030"><label>30</label><element-citation publication-type="journal"><name><surname>Ashwal-Fluss</surname><given-names>R</given-names></name><name><surname>Meyer</surname><given-names>M</given-names></name><name><surname>Pamudurti</surname><given-names>NR</given-names></name><name><surname>Ivanov</surname><given-names>A</given-names></name><name><surname>Bartok</surname><given-names>O</given-names></name><name><surname>Hanan</surname><given-names>M</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>circRNA biogenesis competes with pre-mRNA splicing</article-title><source>Mol Cell</source><year>2014</year><volume>56</volume><fpage>55</fpage><comment>&#x02013;</comment><lpage>66</lpage><pub-id pub-id-type="pmid">25242144</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_031"><label>31</label><element-citation publication-type="journal"><name><surname>Lei</surname><given-names>M</given-names></name><name><surname>Zheng</surname><given-names>G</given-names></name><name><surname>Ning</surname><given-names>Q</given-names></name><name><surname>Zheng</surname><given-names>J</given-names></name><name><surname>Dong</surname><given-names>D</given-names></name><article-title>Translation and functional roles of circular RNAs in human cancer</article-title><source>Mol Cancer</source><year>2020</year><volume>19</volume><fpage>30</fpage><pub-id pub-id-type="pmid">32059672</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_032"><label>32</label><element-citation publication-type="journal"><name><surname>Vo</surname><given-names>JN</given-names></name><name><surname>Cieslik</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Shukla</surname><given-names>S</given-names></name><name><surname>Xiao</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>The Landscape of Circular RNA in Cancer</article-title><source>Cell</source><year>2019</year><volume>176</volume><fpage>869</fpage><comment>&#x02013;</comment><lpage>881</lpage><pub-id pub-id-type="pmid">30735636</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_033"><label>33</label><element-citation publication-type="journal"><name><surname>Zheng</surname><given-names>Q</given-names></name><name><surname>Bao</surname><given-names>C</given-names></name><name><surname>Guo</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>B</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Circular RNA profiling reveals an abundant circHIPK3 that regulates cell growth by sponging multiple miRNAs</article-title><source>Nat Commun</source><year>2016</year><volume>7</volume><fpage>11215</fpage><pub-id pub-id-type="pmid">27050392</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_034"><label>34</label><element-citation publication-type="journal"><name><surname>Xia</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Ye</surname><given-names>B</given-names></name><name><surname>Du</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Xiong</surname><given-names>Z</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>A Circular RNA Protects Dormant Hematopoietic Stem Cells from DNA Sensor cGAS-Mediated Exhaustion</article-title><source>Immunity</source><year>2018</year><volume>48</volume><fpage>688</fpage><comment>&#x02013;</comment><lpage>701</lpage><pub-id pub-id-type="pmid">29625897</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_035"><label>35</label><element-citation publication-type="journal"><name><surname>Westholm</surname><given-names>JO</given-names></name><name><surname>Miura</surname><given-names>P</given-names></name><name><surname>Olson</surname><given-names>S</given-names></name><name><surname>Shenker</surname><given-names>S</given-names></name><name><surname>Joseph</surname><given-names>B</given-names></name><name><surname>Sanfilippo</surname><given-names>P</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Genome-wide analysis of drosophila circular RNAs reveals their structural and sequence properties and age-dependent neural accumulation</article-title><source>Cell Rep</source><year>2014</year><volume>9</volume><fpage>1966</fpage><comment>&#x02013;</comment><lpage>1980</lpage><pub-id pub-id-type="pmid">25544350</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_036"><label>36</label><element-citation publication-type="journal"><name><surname>Xiao</surname><given-names>MS</given-names></name><name><surname>Ai</surname><given-names>Y</given-names></name><name><surname>Wilusz</surname><given-names>JE</given-names></name><article-title>Biogenesis and Functions of Circular RNAs Come into Focus</article-title><source>Trends Cell Biol</source><year>2020</year><volume>30</volume><fpage>226</fpage><comment>&#x02013;</comment><lpage>240</lpage><pub-id pub-id-type="pmid">31973951</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_037"><label>37</label><element-citation publication-type="journal"><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Deng</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Chang</surname><given-names>Z</given-names></name><name><surname>Lu</surname><given-names>Q</given-names></name><name><surname>Tang</surname><given-names>A</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Circular RNA KIF4A Promotes Liver Metastasis of Breast Cancer by Reprogramming Glucose Metabolism</article-title><source>J Oncol</source><year>2022</year><volume>2022</volume><fpage>8035083</fpage><pub-id pub-id-type="pmid">36052282</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_038"><label>38</label><element-citation publication-type="journal"><name><surname>Memczak</surname><given-names>S</given-names></name><name><surname>Jens</surname><given-names>M</given-names></name><name><surname>Elefsinioti</surname><given-names>A</given-names></name><name><surname>Torti</surname><given-names>F</given-names></name><name><surname>Krueger</surname><given-names>J</given-names></name><name><surname>Rybak</surname><given-names>A</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Circular RNAs are a large class of animal RNAs with regulatory potency</article-title><source>Nature</source><year>2013</year><volume>495</volume><fpage>333</fpage><comment>&#x02013;</comment><lpage>338</lpage><pub-id pub-id-type="pmid">23446348</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_039"><label>39</label><element-citation publication-type="journal"><name><surname>Guo</surname><given-names>JU</given-names></name><name><surname>Agarwal</surname><given-names>V</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Bartel</surname><given-names>DP</given-names></name><article-title>Expanded identification and characterization of mammalian circular RNAs</article-title><source>Genome Biol</source><year>2014</year><volume>15</volume><fpage>409</fpage><pub-id pub-id-type="pmid">25070500</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_040"><label>40</label><element-citation publication-type="journal"><name><surname>Perriman</surname><given-names>R</given-names></name><name><surname>Ares M</surname><given-names>Jr</given-names></name><article-title>Circular mRNA can direct translation of extremely long repeating-sequence proteins in vivo</article-title><source>RNA</source><year>1998</year><volume>4</volume><fpage>1047</fpage><comment>&#x02013;</comment><lpage>1054</lpage><pub-id pub-id-type="pmid">9740124</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_041"><label>41</label><element-citation publication-type="journal"><name><surname>Pamudurti</surname><given-names>NR</given-names></name><name><surname>Bartok</surname><given-names>O</given-names></name><name><surname>Jens</surname><given-names>M</given-names></name><name><surname>Ashwal-Fluss</surname><given-names>R</given-names></name><name><surname>Stottmeister</surname><given-names>C</given-names></name><name><surname>Ruhe</surname><given-names>L</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Translation of CircRNAs</article-title><source>Mol Cell</source><year>2017</year><volume>66</volume><fpage>9</fpage><comment>&#x02013;</comment><lpage>21</lpage><pub-id pub-id-type="pmid">28344080</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_042"><label>42</label><element-citation publication-type="journal"><name><surname>Abe</surname><given-names>N</given-names></name><name><surname>Matsumoto</surname><given-names>K</given-names></name><name><surname>Nishihara</surname><given-names>M</given-names></name><name><surname>Nakano</surname><given-names>Y</given-names></name><name><surname>Shibata</surname><given-names>A</given-names></name><name><surname>Maruyama</surname><given-names>H</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Rolling Circle Translation of Circular RNA in Living Human Cells</article-title><source>Sci Rep</source><year>2015</year><volume>5</volume><fpage>16435</fpage><pub-id pub-id-type="pmid">26553571</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_043"><label>43</label><element-citation publication-type="journal"><name><surname>Liu</surname><given-names>CX</given-names></name><name><surname>Chen</surname><given-names>LL</given-names></name><article-title>Circular RNAs: characterization, cellular roles, and applications</article-title><source>Cell</source><year>2022</year><volume>185</volume><fpage>2016</fpage><comment>&#x02013;</comment><lpage>34</lpage><pub-id pub-id-type="pmid">35584701</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_044"><label>44</label><element-citation publication-type="journal"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>XO</given-names></name><name><surname>Chen</surname><given-names>T</given-names></name><name><surname>Xiang</surname><given-names>JF</given-names></name><name><surname>Yin</surname><given-names>QF</given-names></name><name><surname>Xing</surname><given-names>YH</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Circular intronic long noncoding RNAs</article-title><source>Mol Cell</source><year>2013</year><volume>51</volume><fpage>792</fpage><comment>&#x02013;</comment><lpage>806</lpage><pub-id pub-id-type="pmid">24035497</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_045"><label>45</label><element-citation publication-type="journal"><name><surname>Rahmani-Kukia</surname><given-names>N</given-names></name><name><surname>Abbasi</surname><given-names>A</given-names></name><article-title>New insights on circular RNAs and their potential applications as biomarkers, therapeutic agents, and preventive vaccines in viral infections: with a glance at SARS-CoV-2</article-title><source>Mol Ther Nucleic Acids</source><year>2022</year><volume>29</volume><fpage>705</fpage><comment>&#x02013;</comment><lpage>717</lpage><pub-id pub-id-type="pmid">35992045</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_046"><label>46</label><element-citation publication-type="journal"><name><surname>Chen</surname><given-names>CK</given-names></name><name><surname>Cheng</surname><given-names>R</given-names></name><name><surname>Demeter</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Weingarten-Gabbay</surname><given-names>S</given-names></name><name><surname>Jiang</surname><given-names>L</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Structured elements drive extensive circular RNA translation</article-title><source>Mol Cell</source><year>2021</year><volume>81</volume><fpage>4300</fpage><comment>&#x02013;</comment><lpage>4318</lpage><pub-id pub-id-type="pmid">34437836</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_047"><label>47</label><element-citation publication-type="journal"><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Fan</surname><given-names>X</given-names></name><name><surname>Mao</surname><given-names>M</given-names></name><name><surname>Song</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Extensive translation of circular RNAs driven by N6-methyladenosine</article-title><source>Cell Res</source><year>2017</year><volume>27</volume><fpage>626</fpage><comment>&#x02013;</comment><lpage>641</lpage><pub-id pub-id-type="pmid">28281539</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_048"><label>48</label><element-citation publication-type="journal"><name><surname>Tang</surname><given-names>C</given-names></name><name><surname>Xie</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Woolsey</surname><given-names>RJ</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>m6A-dependent biogenesis of circular RNAs in male germ cells</article-title><source>Cell Res</source><year>2020</year><volume>30</volume><fpage>211</fpage><comment>&#x02013;</comment><lpage>228</lpage><pub-id pub-id-type="pmid">32047269</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_049"><label>49</label><element-citation publication-type="journal"><name><surname>Liang</surname><given-names>WC</given-names></name><name><surname>Wong</surname><given-names>CW</given-names></name><name><surname>Liang</surname><given-names>PP</given-names></name><name><surname>Shi</surname><given-names>M</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Rao</surname><given-names>ST</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Translation of the circular RNA circ&#x003b2;-catenin promotes liver cancer cell growth through activation of the Wnt pathway</article-title><source>Genome Biol</source><year>2019</year><volume>20</volume><fpage>84</fpage><pub-id pub-id-type="pmid">31027518</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_050"><label>50</label><element-citation publication-type="journal"><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Yan</surname><given-names>S</given-names></name><name><surname>Sun</surname><given-names>C</given-names></name><name><surname>Xiao</surname><given-names>F</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Novel Role of FBXW7 Circular RNA in Repressing Glioma Tumorigenesis</article-title><source>J Natl Cancer Inst</source><year>2018</year><volume>110</volume><fpage>304</fpage><comment>&#x02013;</comment><lpage>315</lpage><pub-id pub-id-type="pmid">28903484</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_051"><label>51</label><element-citation publication-type="journal"><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>K</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Yan</surname><given-names>S</given-names></name><name><surname>Wei</surname><given-names>P</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>A peptide encoded by circular form of LINC-PINT suppresses oncogenic transcriptional elongation in glioblastoma</article-title><source>Nat Commun</source><year>2018</year><volume>9</volume><fpage>4475</fpage><pub-id pub-id-type="pmid">30367041</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_052"><label>52</label><element-citation publication-type="journal"><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>N</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Yan</surname><given-names>S</given-names></name><name><surname>Xiao</surname><given-names>F</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>A novel protein encoded by the circular form of the SHPRH gene suppresses glioma tumorigenesis</article-title><source>Oncogene</source><year>2018</year><volume>37</volume><fpage>1805</fpage><comment>&#x02013;</comment><lpage>1814</lpage><pub-id pub-id-type="pmid">29343848</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_053"><label>53</label><element-citation publication-type="journal"><name><surname>Legnini</surname><given-names>I</given-names></name><name><surname>Di</surname><given-names>Timoteo G</given-names></name><name><surname>Rossi</surname><given-names>F</given-names></name><name><surname>Morlando</surname><given-names>M</given-names></name><name><surname>Briganti</surname><given-names>F</given-names></name><name><surname>Sthandier</surname><given-names>O</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Circ-ZNF609 Is a Circular RNA that Can Be Translated and Functions in Myogenesis</article-title><source>Mol Cell</source><year>2017</year><volume>66</volume><fpage>22</fpage><comment>&#x02013;</comment><lpage>37</lpage><pub-id pub-id-type="pmid">28344082</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_054"><label>54</label><element-citation publication-type="journal"><name><surname>Ju</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Son</surname><given-names>G</given-names></name><name><surname>Han</surname><given-names>J</given-names></name><article-title>Circular RNAs in and out of Cells: Therapeutic Usages of Circular RNAs</article-title><source>Mol Cells</source><year>2023</year><volume>46</volume><fpage>33</fpage><comment>&#x02013;</comment><lpage>40</lpage><pub-id pub-id-type="pmid">36697235</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_055"><label>55</label><element-citation publication-type="journal"><name><surname>Fischer</surname><given-names>JW</given-names></name><name><surname>Leung</surname><given-names>AK</given-names></name><article-title>CircRNAs: a regulator of cellular stress</article-title><source>Crit Rev Biochem Mol Biol</source><year>2017</year><volume>52</volume><fpage>220</fpage><comment>&#x02013;</comment><lpage>233</lpage><pub-id pub-id-type="pmid">28095716</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_056"><label>56</label><element-citation publication-type="journal"><name><surname>Enuka</surname><given-names>Y</given-names></name><name><surname>Lauriola</surname><given-names>M</given-names></name><name><surname>Feldman</surname><given-names>ME</given-names></name><name><surname>Sas-Chen</surname><given-names>A</given-names></name><name><surname>Ulitsky</surname><given-names>I</given-names></name><name><surname>Yarden</surname><given-names>Y</given-names></name><article-title>Circular RNAs are long-lived and display only minimal early alterations in response to a growth factor</article-title><source>Nucleic Acids Res</source><year>2016</year><volume>44</volume><fpage>1370</fpage><comment>&#x02013;</comment><lpage>1383</lpage><pub-id pub-id-type="pmid">26657629</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_057"><label>57</label><element-citation publication-type="journal"><name><surname>Kramer</surname><given-names>MC</given-names></name><name><surname>Liang</surname><given-names>D</given-names></name><name><surname>Tatomer</surname><given-names>DC</given-names></name><name><surname>Gold</surname><given-names>B</given-names></name><name><surname>March</surname><given-names>ZM</given-names></name><name><surname>Cherry</surname><given-names>S</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Combinatorial control of Drosophila circular RNA expression by intronic repeats, hnRNPs, and SR proteins</article-title><source>Genes Dev</source><year>2015</year><volume>29</volume><fpage>2168</fpage><comment>&#x02013;</comment><lpage>2182</lpage><pub-id pub-id-type="pmid">26450910</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_058"><label>58</label><element-citation publication-type="journal"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>CX</given-names></name><name><surname>Xue</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>S</given-names></name><name><surname>Yin</surname><given-names>QF</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Coordinated circRNA Biogenesis and Function with NF90/NF110 in Viral Infection</article-title><source>Mol Cell</source><year>2017</year><volume>67</volume><fpage>214</fpage><comment>&#x02013;</comment><lpage>227</lpage><pub-id pub-id-type="pmid">28625552</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_059"><label>59</label><element-citation publication-type="journal"><name><surname>Wilusz</surname><given-names>JE</given-names></name><article-title>A 360&#x000b0; view of circular RNAs: From biogenesis to functions</article-title><source>Wiley Interdiscip Rev RNA</source><year>2018</year><volume>9</volume><fpage>e1478</fpage><pub-id pub-id-type="pmid">29655315</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_060"><label>60</label><element-citation publication-type="journal"><name><surname>Pamudurti</surname><given-names>NR</given-names></name><name><surname>Bartok</surname><given-names>O</given-names></name><name><surname>Jens</surname><given-names>M</given-names></name><name><surname>Ashwal-Fluss</surname><given-names>R</given-names></name><name><surname>Stottmeister</surname><given-names>C</given-names></name><name><surname>Ruhe</surname><given-names>L</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Translation of CircRNAs</article-title><source>Mol Cell</source><year>2017</year><volume>66</volume><fpage>9</fpage><comment>&#x02013;</comment><lpage>21</lpage><pub-id pub-id-type="pmid">28344080</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_061"><label>61</label><element-citation publication-type="journal"><name><surname>Weigelt</surname><given-names>CM</given-names></name><name><surname>Sehgal</surname><given-names>R</given-names></name><name><surname>Tain</surname><given-names>LS</given-names></name><name><surname>Cheng</surname><given-names>J</given-names></name><name><surname>E&#x000df;er</surname><given-names>J</given-names></name><name><surname>Pahl</surname><given-names>A</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>An Insulin-Sensitive Circular RNA that Regulates Lifespan in Drosophila</article-title><source>Mol Cell</source><year>2020</year><volume>79</volume><fpage>268</fpage><comment>&#x02013;</comment><lpage>279</lpage><pub-id pub-id-type="pmid">32592682</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_062"><label>62</label><element-citation publication-type="journal"><name><surname>Gu</surname><given-names>C</given-names></name><name><surname>Zhou</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Kou</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>S</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>circGprc5a Promoted Bladder Oncogenesis and Metastasis through Gprc5a-Targeting Peptide</article-title><source>Mol Ther Nucleic Acids</source><year>2018</year><volume>13</volume><fpage>633</fpage><comment>&#x02013;</comment><lpage>641</lpage><pub-id pub-id-type="pmid">30497053</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_063"><label>63</label><element-citation publication-type="journal"><name><surname>Chen</surname><given-names>YG</given-names></name><name><surname>Kim</surname><given-names>MV</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Batista</surname><given-names>PJ</given-names></name><name><surname>Aoyama</surname><given-names>S</given-names></name><name><surname>Wilusz</surname><given-names>JE</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Sensing Self and Foreign Circular RNAs by Intron Identity</article-title><source>Mol Cell</source><year>2017</year><volume>67</volume><fpage>228</fpage><comment>&#x02013;</comment><lpage>238</lpage><pub-id pub-id-type="pmid">28625551</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_064"><label>64</label><element-citation publication-type="journal"><name><surname>Abe</surname><given-names>N</given-names></name><name><surname>Hiroshima</surname><given-names>M</given-names></name><name><surname>Maruyama</surname><given-names>H</given-names></name><name><surname>Nakashima</surname><given-names>Y</given-names></name><name><surname>Nakano</surname><given-names>Y</given-names></name><name><surname>Matsuda</surname><given-names>A</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Rolling circle amplification in a prokaryotic translation system using small circular RNA</article-title><source>Angew Chem Int Ed Engl</source><year>2013</year><volume>52</volume><fpage>7004</fpage><comment>&#x02013;</comment><lpage>7008</lpage><pub-id pub-id-type="pmid">23716491</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_065"><label>65</label><element-citation publication-type="journal"><name><surname>Chen</surname><given-names>CY</given-names></name><name><surname>Sarnow</surname><given-names>P</given-names></name><article-title>Initiation of protein synthesis by the eukaryotic translational apparatus on circular RNAs</article-title><source>Science</source><year>1995</year><volume>268</volume><fpage>415</fpage><comment>&#x02013;</comment><lpage>417</lpage><pub-id pub-id-type="pmid">7536344</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_066"><label>66</label><element-citation publication-type="journal"><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>SK</given-names></name><name><surname>Belk</surname><given-names>JA</given-names></name><name><surname>Amaya</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Cardenas</surname><given-names>A</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Engineering circular RNA for enhanced protein production</article-title><source>Nat Biotechnol</source><year>2023</year><volume>41</volume><fpage>262</fpage><comment>&#x02013;</comment><lpage>272</lpage><pub-id pub-id-type="pmid">35851375</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_067"><label>67</label><element-citation publication-type="journal"><name><surname>Costello</surname><given-names>A</given-names></name><name><surname>Lao</surname><given-names>NT</given-names></name><name><surname>Barron</surname><given-names>N</given-names></name><name><surname>Clynes</surname><given-names>M</given-names></name><article-title>Continuous translation of circularized mRNA improves recombinant protein titer</article-title><source>Metab Eng</source><year>2019</year><volume>52</volume><fpage>284</fpage><comment>&#x02013;</comment><lpage>292</lpage><pub-id pub-id-type="pmid">30615942</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_068"><label>68</label><element-citation publication-type="journal"><name><surname>Pardi</surname><given-names>N</given-names></name><name><surname>Hogan</surname><given-names>MJ</given-names></name><name><surname>Porter</surname><given-names>FW</given-names></name><name><surname>Weissman</surname><given-names>D</given-names></name><article-title>mRNA vaccines - a new era in vaccinology</article-title><source>Nat Rev Drug Discov</source><year>2018</year><volume>17</volume><fpage>261</fpage><comment>&#x02013;</comment><lpage>279</lpage><pub-id pub-id-type="pmid">29326426</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_069"><label>69</label><element-citation publication-type="journal"><name><surname>Wesselhoeft</surname><given-names>RA</given-names></name><name><surname>Kowalski</surname><given-names>PS</given-names></name><name><surname>Anderson</surname><given-names>DG</given-names></name><article-title>Engineering circular RNA for potent and stable translation in eukaryotic cells</article-title><source>Nat Commun</source><year>2018</year><volume>9</volume><fpage>2629</fpage><pub-id pub-id-type="pmid">29980667</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_070"><label>70</label><element-citation publication-type="journal"><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Du</surname><given-names>Y</given-names></name><name><surname>Tan</surname><given-names>Y</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Intratumoral delivered novel circular mRNA encoding cytokines for immune modulation and cancer therapy</article-title><source>Mol Ther Nucleic Acids</source><year>2022</year><volume>30</volume><fpage>184</fpage><comment>&#x02013;</comment><lpage>197</lpage><pub-id pub-id-type="pmid">36156907</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_071"><label>71</label><element-citation publication-type="journal"><name><surname>Qu</surname><given-names>L</given-names></name><name><surname>Yi</surname><given-names>Z</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Circular RNA vaccines against SARS-CoV-2 and emerging variants</article-title><source>Cell</source><year>2022</year><volume>185</volume><fpage>1728</fpage><comment>&#x02013;</comment><lpage>1744</lpage><pub-id pub-id-type="pmid">35460644</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_072"><label>72</label><element-citation publication-type="journal"><name><surname>Wadhwa</surname><given-names>A</given-names></name><name><surname>Aljabbari</surname><given-names>A</given-names></name><name><surname>Lokras</surname><given-names>A</given-names></name><name><surname>Foged</surname><given-names>C</given-names></name><name><surname>Thakur</surname><given-names>A</given-names></name><article-title>Opportunities and Challenges in the Delivery of mRNA-based Vaccines</article-title><source>Pharmaceutics</source><year>2020</year><volume>12</volume><fpage>102</fpage><pub-id pub-id-type="pmid">32013049</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_073"><label>73</label><element-citation publication-type="journal"><name><surname>Hobernik</surname><given-names>D</given-names></name><name><surname>Bros</surname><given-names>M</given-names></name><article-title>DNA Vaccines-How Far From Clinical Use?</article-title><source>Int J Mol Sci</source><year>2018</year><volume>19</volume><fpage>3605</fpage><pub-id pub-id-type="pmid">30445702</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_074"><label>74</label><element-citation publication-type="journal"><name><surname>Szab&#x000f3;</surname><given-names>GT</given-names></name><name><surname>Mahiny</surname><given-names>AJ</given-names></name><name><surname>Vlatkovic</surname><given-names>I</given-names></name><article-title>COVID-19 mRNA vaccines: Platforms and current developments</article-title><source>Mol Ther</source><year>2022</year><volume>30</volume><fpage>1850</fpage><comment>&#x02013;</comment><lpage>1868</lpage><pub-id pub-id-type="pmid">35189345</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_075"><label>75</label><element-citation publication-type="journal"><name><surname>Ti</surname><given-names>D</given-names></name><name><surname>Yan</surname><given-names>X</given-names></name><name><surname>Wei</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Han</surname><given-names>W</given-names></name><article-title>Inducing immunogenic cell death in immuno-oncological therapies</article-title><source>Chin J Cancer Res</source><year>2022</year><volume>34</volume><fpage>1</fpage><comment>-</comment><lpage>10</lpage><pub-id pub-id-type="pmid">35355932</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_076"><label>76</label><element-citation publication-type="journal"><name><surname>Petkovic</surname><given-names>S</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>S</given-names></name><article-title>Synthesis and Engineering of Circular RNAs</article-title><source>Methods Mol Biol</source><year>2018</year><volume>1724</volume><fpage>167</fpage><comment>&#x02013;</comment><lpage>180</lpage><pub-id pub-id-type="pmid">29322449</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_077"><label>77</label><element-citation publication-type="journal"><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Muisha</surname><given-names>MB</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><article-title>Research Progress on N6-adenosylate Methylation RNA Modification in Heart Failure Remodeling</article-title><source>J Transl Int Med</source><year>2023</year><volume>10</volume><fpage>340</fpage><comment>&#x02013;</comment><lpage>348</lpage><pub-id pub-id-type="pmid">36860637</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_078"><label>78</label><element-citation publication-type="journal"><name><surname>Meyer</surname><given-names>KD</given-names></name><name><surname>Saletore</surname><given-names>Y</given-names></name><name><surname>Zumbo</surname><given-names>P</given-names></name><name><surname>Elemento</surname><given-names>O</given-names></name><name><surname>Mason</surname><given-names>CE</given-names></name><name><surname>Jaffrey</surname><given-names>SR</given-names></name><article-title>Comprehensive analysis of mRNA methylation reveals enrichment in 3' UTRs and near stop codons</article-title><source>Cell</source><year>2012</year><volume>149</volume><fpage>1635</fpage><comment>&#x02013;</comment><lpage>1646</lpage><pub-id pub-id-type="pmid">22608085</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_079"><label>79</label><element-citation publication-type="journal"><name><surname>Obi</surname><given-names>P</given-names></name><name><surname>Chen</surname><given-names>YG</given-names></name><article-title>The design and synthesis of circular RNAs</article-title><source>Methods</source><year>2021</year><volume>196</volume><fpage>85</fpage><comment>&#x02013;</comment><lpage>103</lpage><pub-id pub-id-type="pmid">33662562</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_080"><label>80</label><element-citation publication-type="journal"><name><surname>Di</surname><given-names>Timoteo G</given-names></name><name><surname>Dattilo</surname><given-names>D</given-names></name><name><surname>Centr&#x000f3;n-Broco</surname><given-names>A</given-names></name><name><surname>Colantoni</surname><given-names>A</given-names></name><name><surname>Guarnacci</surname><given-names>M</given-names></name><name><surname>Rossi</surname><given-names>F</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Modulation of circRNA Metabolism by m6A Modification</article-title><source>Cell Rep</source><year>2020</year><volume>31</volume><fpage>107641</fpage><pub-id pub-id-type="pmid">32402287</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_081"><label>81</label><element-citation publication-type="journal"><name><surname>Usman</surname><given-names>N</given-names></name><name><surname>Cedergren</surname><given-names>R</given-names></name><article-title>Exploiting the chemical synthesis of RNA</article-title><source>Trends Biochem Sci</source><year>1992</year><volume>17</volume><fpage>334</fpage><comment>&#x02013;</comment><lpage>339</lpage><pub-id pub-id-type="pmid">1384179</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_082"><label>82</label><element-citation publication-type="journal"><name><surname>Rong</surname><given-names>M</given-names></name><name><surname>He</surname><given-names>B</given-names></name><name><surname>McAllister</surname><given-names>WT</given-names></name><name><surname>Durbin</surname><given-names>RK</given-names></name><article-title>Promoter specificity determinants of T7 RNA polymerase</article-title><source>Proc Natl Acad Sci U S A</source><year>1998</year><volume>95</volume><fpage>515</fpage><comment>&#x02013;</comment><lpage>519</lpage><pub-id pub-id-type="pmid">9435223</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_083"><label>83</label><element-citation publication-type="journal"><name><surname>Dolinnaya</surname><given-names>NG</given-names></name><name><surname>Sokolova</surname><given-names>NI</given-names></name><name><surname>Ashirbekova</surname><given-names>DT</given-names></name><name><surname>Shabarova</surname><given-names>ZA</given-names></name><article-title>The use of BrCN for assembling modified DNA duplexes and DNA-RNA hybrids; comparison with water-soluble carbodiimide</article-title><source>Nucleic Acids Res</source><year>1991</year><volume>19</volume><fpage>3067</fpage><comment>&#x02013;</comment><lpage>3072</lpage><pub-id pub-id-type="pmid">1711679</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_084"><label>84</label><element-citation publication-type="journal"><name><surname>M&#x000fc;ller</surname><given-names>S</given-names></name><name><surname>Appel</surname><given-names>B</given-names></name><article-title>In vitro circularization of RNA</article-title><source>RNA Biol</source><year>2017</year><volume>14</volume><fpage>1018</fpage><comment>&#x02013;</comment><lpage>1027</lpage><pub-id pub-id-type="pmid">27668458</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_085"><label>85</label><element-citation publication-type="journal"><name><surname>Miller</surname><given-names>ES</given-names></name><name><surname>Kutter</surname><given-names>E</given-names></name><name><surname>Mosig</surname><given-names>G</given-names></name><name><surname>Arisaka</surname><given-names>F</given-names></name><name><surname>Kunisawa</surname><given-names>T</given-names></name><name><surname>R&#x000fc;ger</surname><given-names>W</given-names></name><article-title>Bacteriophage T4 genome</article-title><source>Microbiol Mol Biol Rev</source><year>2003</year><volume>67</volume><fpage>86</fpage><comment>-</comment><lpage>156</lpage><comment>table of contents</comment><pub-id pub-id-type="pmid">12626685</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_086"><label>86</label><element-citation publication-type="journal"><name><surname>Remaut</surname><given-names>E</given-names></name><name><surname>Tsao</surname><given-names>H</given-names></name><name><surname>Fiers</surname><given-names>W</given-names></name><article-title>Improved plasmid vectors with a thermoinducible expression and temperature-regulated runaway replication</article-title><source>Gene</source><year>1983</year><volume>22</volume><fpage>103</fpage><comment>&#x02013;</comment><lpage>113</lpage><pub-id pub-id-type="pmid">6305768</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_087"><label>87</label><element-citation publication-type="journal"><name><surname>Petkovic</surname><given-names>S</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>S</given-names></name><article-title>RNA circularization strategies in vivo and in vitro</article-title><source>Nucleic Acids Res</source><year>2015</year><volume>43</volume><fpage>2454</fpage><comment>&#x02013;</comment><lpage>2465</lpage><pub-id pub-id-type="pmid">25662225</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_088"><label>88</label><element-citation publication-type="journal"><name><surname>M&#x000fc;ller</surname><given-names>S</given-names></name><name><surname>Appel</surname><given-names>B</given-names></name><article-title>In vitro circularization of RNA</article-title><source>RNA Biol</source><year>2017</year><volume>14</volume><fpage>1018</fpage><comment>&#x02013;</comment><lpage>1027</lpage><pub-id pub-id-type="pmid">27668458</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_089"><label>89</label><element-citation publication-type="journal"><name><surname>Mikheeva</surname><given-names>S</given-names></name><name><surname>Hakim-Zargar</surname><given-names>M</given-names></name><name><surname>Carlson</surname><given-names>D</given-names></name><name><surname>Jarrell</surname><given-names>K</given-names></name><article-title>Use of an engineered ribozyme to produce a circular human exon</article-title><source>Nucleic Acids Res</source><year>1997</year><volume>25</volume><fpage>5085</fpage><comment>&#x02013;</comment><lpage>5094</lpage><pub-id pub-id-type="pmid">9396820</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_090"><label>90</label><element-citation publication-type="journal"><name><surname>Jarrell</surname><given-names>KA</given-names></name><article-title>Inverse splicing of a group II intron</article-title><source>Proc Natl Acad Sci U S A</source><year>1993</year><volume>90</volume><fpage>8624</fpage><comment>&#x02013;</comment><lpage>8627</lpage><pub-id pub-id-type="pmid">8378340</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_091"><label>91</label><element-citation publication-type="journal"><name><surname>Puttaraju</surname><given-names>M</given-names></name><name><surname>Been</surname><given-names>MD</given-names></name><article-title>Circular ribozymes generated in Escherichia coli using group I self-splicing permuted intron-exon sequences</article-title><source>J Biol Chem</source><year>1996</year><volume>271</volume><fpage>26081</fpage><comment>&#x02013;</comment><lpage>26087</lpage><pub-id pub-id-type="pmid">8824250</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_092"><label>92</label><element-citation publication-type="journal"><name><surname>Puttaraju</surname><given-names>M</given-names></name><name><surname>Been</surname><given-names>MD</given-names></name><article-title>Group I permuted intron-exon (PIE) sequences self-splice to produce circular exons</article-title><source>Nucleic Acids Res</source><year>1992</year><volume>20</volume><fpage>5357</fpage><comment>&#x02013;</comment><lpage>5364</lpage><pub-id pub-id-type="pmid">1279519</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_093"><label>93</label><element-citation publication-type="journal"><name><surname>Murray</surname><given-names>HL</given-names></name><name><surname>Mikheeva</surname><given-names>S</given-names></name><name><surname>Coljee</surname><given-names>VW</given-names></name><name><surname>Turczyk</surname><given-names>BM</given-names></name><name><surname>Donahue</surname><given-names>WF</given-names></name><name><surname>Bar-Shalom</surname><given-names>A</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Excision of group II introns as circles</article-title><source>Mol Cell</source><year>2001</year><volume>8</volume><fpage>201</fpage><comment>&#x02013;</comment><lpage>211</lpage><pub-id pub-id-type="pmid">11511373</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_094"><label>94</label><element-citation publication-type="journal"><name><surname>Orme</surname><given-names>IM</given-names></name><name><surname>Henao-Tamayo</surname><given-names>MI</given-names></name><article-title>Trying to See the Forest through the Trees: Deciphering the Nature of Memory Immunity to Mycobacterium tuberculosis</article-title><source>Front Immunol</source><year>2018</year><volume>9</volume><fpage>461</fpage><pub-id pub-id-type="pmid">29568298</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_095"><label>95</label><element-citation publication-type="journal"><name><surname>Irvine</surname><given-names>DJ</given-names></name><name><surname>Aung</surname><given-names>A</given-names></name><name><surname>Silva</surname><given-names>M</given-names></name><article-title>Controlling timing and location in vaccines</article-title><source>Adv Drug Deliv Rev</source><year>2020</year><volume>158</volume><fpage>91</fpage><comment>&#x02013;</comment><lpage>115</lpage><pub-id pub-id-type="pmid">32598970</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_096"><label>96</label><element-citation publication-type="journal"><name><surname>Jeck</surname><given-names>WR</given-names></name><name><surname>Sorrentino</surname><given-names>JA</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Slevin</surname><given-names>MK</given-names></name><name><surname>Burd</surname><given-names>CE</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Circular RNAs are abundant, conserved, and associated with ALU repeats</article-title><source>RNA</source><year>2013</year><volume>19</volume><fpage>141</fpage><comment>&#x02013;</comment><lpage>157</lpage><pub-id pub-id-type="pmid">23249747</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_097"><label>97</label><element-citation publication-type="journal"><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Zeng</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><article-title>Transcutaneous delivery of DNA/mRNA for cancer therapeutic vaccination</article-title><source>J Gene Med</source><year>2019</year><volume>21</volume><fpage>e3089</fpage><pub-id pub-id-type="pmid">30958606</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_098"><label>98</label><element-citation publication-type="journal"><name><surname>Tam</surname><given-names>YY</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Cullis</surname><given-names>PR</given-names></name><article-title>Advances in Lipid Nanoparticles for siRNA Delivery</article-title><source>Pharmaceutics</source><year>2013</year><volume>5</volume><fpage>498</fpage><comment>&#x02013;</comment><lpage>507</lpage><pub-id pub-id-type="pmid">24300520</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_099"><label>99</label><element-citation publication-type="journal"><name><surname>Chaudhary</surname><given-names>N</given-names></name><name><surname>Weissman</surname><given-names>D</given-names></name><name><surname>Whitehead</surname><given-names>KA</given-names></name><article-title>mRNA vaccines for infectious diseases: principles, delivery and clinical translation</article-title><source>Nat Rev Drug Discov</source><year>2021</year><volume>20</volume><fpage>817</fpage><comment>&#x02013;</comment><lpage>838</lpage><pub-id pub-id-type="pmid">34433919</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_100"><label>100</label><element-citation publication-type="journal"><name><surname>Wesselhoeft</surname><given-names>RA</given-names></name><name><surname>Kowalski</surname><given-names>PS</given-names></name><name><surname>Parker-Hale</surname><given-names>FC</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Bisaria</surname><given-names>N</given-names></name><name><surname>Anderson</surname><given-names>DG</given-names></name><article-title>RNA Circularization Diminishes Immunogenicity and Can Extend Translation Duration In Vivo</article-title><source>Mol Cell</source><year>2019</year><volume>74</volume><fpage>508</fpage><comment>&#x02013;</comment><lpage>520</lpage><pub-id pub-id-type="pmid">30902547</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_101"><label>101</label><element-citation publication-type="journal"><name><surname>Bartlett</surname><given-names>BL</given-names></name><name><surname>Pellicane</surname><given-names>AJ</given-names></name><name><surname>Tyring</surname><given-names>SK</given-names></name><article-title>Vaccine immunology</article-title><source>Dermatol Ther</source><year>2009</year><volume>22</volume><issue>2</issue><fpage>104</fpage><comment>&#x02013;</comment><lpage>9</lpage><pub-id pub-id-type="pmid">19335722</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_102"><label>102</label><element-citation publication-type="journal"><name><surname>Hill</surname><given-names>A</given-names></name><name><surname>Beitelshees</surname><given-names>M</given-names></name><name><surname>Pfeifer</surname><given-names>BA</given-names></name><article-title>Vaccine Delivery and Immune Response Basics</article-title><source>Methods Mol Biol</source><year>2021</year><volume>2183</volume><fpage>1</fpage><comment>&#x02013;</comment><lpage>8</lpage><pub-id pub-id-type="pmid">32959236</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_103"><label>103</label><element-citation publication-type="journal"><name><surname>Seephetdee</surname><given-names>C</given-names></name><name><surname>Bhukhai</surname><given-names>K</given-names></name><name><surname>Buasri</surname><given-names>N</given-names></name><name><surname>Leelukkanaveera</surname><given-names>P</given-names></name><name><surname>Lerdwattanasombat</surname><given-names>P</given-names></name><name><surname>Manopwisedjaroen</surname><given-names>S</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>A circular mRNA vaccine prototype producing VFLIP-X spike confers a broad neutralization of SARS-CoV-2 variants by mouse sera</article-title><source>Antiviral Res</source><year>2022</year><volume>204</volume><fpage>105370</fpage><pub-id pub-id-type="pmid">35772601</pub-id>
</element-citation></ref><ref id="j_jtim-2023-0122_ref_104"><label>104</label><element-citation publication-type="journal"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Peng</surname><given-names>K</given-names></name><name><surname>Yang</surname><given-names>K</given-names></name><name><surname>Ma</surname><given-names>W</given-names></name><name><surname>Qi</surname><given-names>S</given-names></name><name><surname>Yu</surname><given-names>X</given-names></name><comment>
<italic toggle="yes">et al.</italic>
</comment><article-title>Circular RNA cancer vaccines drive immunity in hard-to-treat malignancies</article-title><source>Theranostics</source><year>2022</year><volume>12</volume><fpage>6422</fpage><comment>&#x02013;</comment><lpage>6436</lpage><pub-id pub-id-type="pmid">36168634</pub-id>
</element-citation></ref></ref-list></back></article>
